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Loss of tolerance:
 It is important to remember that several missed
doses may mean a loss of tolerance.
 Three days missed consecutively should lead to
a dose review and possible reduction in dose.
 Five days or more missed consecutively should
lead to re-assessment and re-titration.
 The tolerance to opioids maintained by people on
adequate methadone treatment is an important
protective factor against overdose: people on
adequate treatment are far less likely to overdose
than opioid users not in treatment.
Ongoing care:
 Treatment is reviewed at every contact and needs
to be reviewed formally, at least every three to four
months, to measure improvements in health and
well-being.
 A toxicology screen (urine or oral fluid swab) needs
to be taken frequently in the beginning of treatment
and, when stabilised, between two and four times
a year to confirm use of medication and monitor
treatment.
 Toxicology screens should never be used punitively,
but as an aid to treatment.
 Screens positive for heroin, or other drugs, require
a review of treatment and dose and should not normally
lead to the cessation of treatment or dose reduction.
 It is important that patients are given good information
on methadone’s actions and effects and advice on
safe storage of take-home doses.
Shared care:
 Treatment of drug users is multifaceted and normally
requires a multidisciplinary response and, wherever
possible, should be provided in collaboration with
others such as other primary care workers, practice
nurses, dispensing pharmacists, practitioners with
a special interest and addiction specialists.
 Practitioners should only treat and prescribe to the
level of practice at which they feel competent and
confident.
 More stable patients may not need so much
additional input.
 Shared care should be encouraged to meet the
needs of the individual, not a specific drug.
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Summary
Opioid dependence is common in the UK and
methadone is an effective treatment.
Effective:
 Methadone is an effective evidence based medication
used for the treatment of opioid dependence.
 It is most effective when used as a maintenance
agent at optimal dosing.
 Its primary function is to reduce (and eventually replace)
illicit opioid use and in so doing, reduce harm and
improve the health and psychological well-being of
the patient.
Maintenance and detoxification:
 Choosing between maintenance and detoxification
occurs at many points during treatment, starting at
the first assessment and then at various points
as appropriate.
 Methadone can be used as a maintenance intervention
or sometimes as a detoxification agent.
 Other medications, such as buprenorphine and
lofexidine, may be more effective for detoxification
in some patients.
Methadone maintenance:
 Methadone is still considered the gold standard for
long-term opioid dependence.
 Optimal dose for maintenance is usually between
60 to 120 mg daily (some people need more and
some less).
 Methadone is usually prescribed in an oral formulation:
methadone oral solution (mixture) 1 mg/ml.
Assessment:
 Before prescribing methadone, opioid dependence
must first be confirmed by history and examination,
including physical examination, and by toxicology
screening using urine or oral fluid swabs.
Titration:
 Due to the risk of overdose, the starting dose should
be between 10 and 30 mg daily.
 For patients on other sedative drugs, including
benzodiazepines or alcohol, the starting dose
should not be more than 20 mg daily.
 Doses should then be titrated upwards to optimal
levels, usually between 60 and 120 mg.
 Increases of between 5 to 10 mg a day with a
maximum of 30 mg a week for the first two weeks
(after that it can be slightly quicker).
 The consumption of methadone doses should be
supervised for at least the first three months and
until the patient has gained stability, unless there are
important other considerations (e.g. employment,
child care responsibilities) and the risk of diversion
has been assessed as low.
 Methadone should initially be prescribed in daily
instalments, on FP10 (MDA) in England and Wales
or GP10 (3) in Scotland.
 It is the responsibility of the prescriber to ensure safe
induction on to methadone. This responsibility cannot
be delegated. However, a close working relationship
with pharmacists and drug workers can be helpful
in facilitating titration to an adequate dose as quickly
as possible.
Stabilisation:
 Stabilisation involves finding a suitable dose that
keeps the patient engaged in treatment without the
need to supplement with other drugs and/or heroin.
 The process of psychosocial stabilisation usually
begins once drug use has begun to stabilise.
Interactions:
 Methadone interacts with other central nervous
system depressants including benzodiazepines,
antidepressants and alcohol, increasing the risk of
overdose and patients must be informed of this.
 It can be particularly dangerous to use any sedative
drugs, including heroin and benzodiazepines, especially
by injection, while taking methadone.
 Drugs that increase metabolism such as rifampicin
or phenytoin, may mean higher doses of methadone
are needed to compensate.
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A summary of the evidence in 1999 concluded that given
the high morbidity and mortality seen in patients with
opioid dependence not in treatment, the public health
challenge was to deliver safe and effective methadone
treatments to as many patients as could benefit from it,
while minimising the risk of diversion of prescribed
medication.14  Whilst methadone clearly remains the
mainstay of the public health response, there has been
an increase recently in the use of buprenorphine for some
patients. Also with more patients now in treatment,
increasing access to psychosocial and other supportive
interventions in addition to the pharmacotherapy is
important.
2. Clinical pharmacology
Methadone is a long acting synthetic opioid analgesic
originally synthesised in 1939. It acts as a full opiate
agonist and is usually used in oral mixture form as a
substitute medication for the dependent use of opioids,
most commonly street heroin. Methadone alleviates
opioid withdrawal symptoms and at adequate doses
blocks the effects of additional opioids, while at the
same time alleviating craving. This can dramatically reduce
and often eliminate the constant need to obtain illicit
opioid drugs.
Relevant properties
Methadone pharmacokinetics display wide variability
between drug dependent individuals according to age,
gender, ethnic background, body mass, prior drug and
health history and is significantly different in opioid
dependent people compared to non-opioid dependent
people.
As a guide:
Time to peak plasma concentration:
 Four hours after oral administration
(range two to six hours).
Time to peak clinical effects:
 Two to four hours for first dose.
 It takes four to five days for methadone tissue and
plasma levels to stabilise, though accumulation
continues beyond this to finally reach a steady state
by ten days.30, 31
 Once a steady state is reached variations in blood
concentration levels are small.
Plasma half-life:
 The length of time that methadone lasts in the
body varies:
 Single one-off dose – shorter than maintenance
dosing 12 to 18 hours, mean 15 hours.
 First few days – between 13 to 112 hours,
mean 37 hours.32
 At the onset of daily dosing half-life is very long
and there is a risk of drug accumulation. For this
reason, methadone induction should be a cautious
and gradual process.
 Elimination half-life normally 20 to 37 hours but
can range up to 91 hours for some individuals
and its rate of clearance from the body can vary
by a factor of almost 100.33
Methadone metabolism:
 Well absorbed from the gastrointestinal tract into
the blood stream.
 Well distributed in body fats.
 Binds well to plasma proteins and to lungs, liver
and kidney tissues.
 Varies enormously in different people and widely
different doses of methadone are needed to create
the same serum methadone level.
 Metabolised through the liver via the cytochrome P450
sub-family of enzymes thus susceptible to
pharmacokinetic interactions with drugs that
inhibit or induce liver enzymes.




This guidance has been produced to aid medical
practitioners and others in the use of methadone as a
substitute medication for opioid dependence for
maintenance and detoxification. It should be read in
conjunction with the Clinical Guidelines, Drug misuse
and dependence: guidelines on clinical management,
issued by the UK Departments of Health in 1999 1 and
National Treatment Agency Research into Practice
briefings: 3, 4 and 5.2, 3, 4
Methadone prescribing in primary care has increased
recently and there is a need for accessible evidence-
based guidance specifically aimed at primary care.5
This guidance is part of a series, which also includes the
use of buprenorphine in opioid dependence treatment,
treatment of cocaine users and hepatitis vaccination
schedules.6, 7, 8
These documents are available online at
www.smmgp.org.uk and www.rcgp.org.uk
Who is the guidance for?
This guidance is aimed at all clinicians involved in the
care of drug using patients. It has been developed
specifically to support the use of methadone in
primary care.
Evidence-based guidance
This guidance draws on the research literature and
experience, both in the UK and internationally, in the
clinical use of methadone. The evidence base for
methadone as a successful treatment for opioid
dependence is extensive and still growing. However,
there are many technical and practical aspects to
managing drug using patients in primary care.
Consequently this document also draws upon
recommendations from experts in the field to
address the evidence gaps.
Treatment for opioid dependence can be effective in
primary care and there is a substantial body of evidence
to support this. There are now a number of substitution
therapies supporting this treatment being used which
include methadone and buprenorphine in the UK and
other therapies in other parts of the world, such as
morphine sulphate in Austria.2, 6, 9
1. Rationale for the use of methadone
There is an increasing body of evidence that the primary
care setting is an effective means of delivering treatment
for opioid dependence.10, 11, 12, 13   Methadone maintenance
treatment (MMT) is now a well-established treatment
modality across a variety of treatment settings and
supported by both research evidence and clinical
practice.14,15,16,17,18,19
The aim of methadone maintenance treatment is to
improve the quality of life of opioid-dependent patients
and to reduce the potential harm of using illicit drugs.
MMT greatly reduces mortality,20  illicit drug use and
criminal activity, and attracts and retains more patients
in treatment than other treatments.9  There is good
evidence that MMT reduces transmission of HIV,21, 22, 23
although the evidence for effectiveness at reducing
transmission of hepatitis B virus and hepatitis C virus
is less convincing.24, 25, 26
There is no evidence that MMT increases the overall
length of dependence.14  The positive outcomes of
MMT are only sustained while patients are in treatment.
Effective treatment of the parent can also have major
benefits for the children of problem drug users.27
Methadone is a highly effective maintenance treatment
for chronic dependent opioid users that can deliver a
wide range of harm reduction outcomes for large numbers
of patients in a wide variety of settings. However,
effectiveness may be reduced by departure from
optimum methods of delivery. Enforced reductions in
the methadone dose and putting pressure on patients
to become abstinent from methadone are associated
with poor outcomes.28
The most effective MMT programmes are those that
provide optimal doses (usually between 60 to120 mg
daily) of methadone as part of a comprehensive treatment
programme, which will include regular reviews, general
medical care and psychosocial support as required,
and which validates maintenance as much as abstinence
as desirable treatment goals 9, 17, 29 and where patients
feel they play a meaningful role in determining their
optimum dose.
Methadone is an effective substitute medication
for opioid dependence for use in UK primary care.
The pharmacokinetics of methadone can vary
considerably between individuals.
Methadone metabolism varies in different people
and different doses of methadone are needed
to create the same serum methadone level.
Optimal doses are usually between 60 to 120 mg
and may exert clinical effects for between 24
to 36 hours; low doses exert clinical effects
for only a few hours.
Tolerance to opioids varies between individuals
and can change in individuals overtime.
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2. Methadone oral solution (concentrated mixture)
10 mg/ml (blue) and 20 mg/ml (brown)
Methadone oral solution also comes in more concentrated
forms, which are different strengths and vary in colour,
such as 10 mg /1 ml and 20 mg/1 ml. These formulations
are used in specialist settings for on-site dispensing.
Experienced practitioners working in primary care may
sometimes use these strengths for patients on high dose
methadone, to reduce the volume taken. However this
would normally be on a supervised consumption basis
as the higher concentration means there is a greater risk
of overdose should it be diverted onto the illicit market
and also because it is not viscous, unlike 1 mg/1ml
formulations and therefore is easier to inject.
Methadone linctus 1 mg/2.5 ml is used in palliative care for the control
of distressing cough in terminal lung cancer. It is not licensed for the
treatment of drug dependence.
3. Methadone tablets 5 mg
Methadone tablets are not licensed for the treatment of
drug dependence. The Advisory Council for the Misuse
of Drugs (ACMD) and the Clinical Guidelines advise
against the prescription of methadone tablets because
they can be injected and have a high street value.1, 36
Their prescribing in general practice is problematic
and not generally advised.
However, some long-term opioid dependent patients
prefer this formulation as tablets are easier to take, have
no unpleasant taste and are more convenient. They may
be justified for specific circumstances such as to prevent
vomiting in pregnancy; nausea due to chemotherapy,
during holidays abroad and where there is proven
intolerance to the mixture, if the prescriber has the level
of experience to prescribe them and has undertaken the
necessary precautions to ensure they are being taken
appropriately. Specialist advice should be taken before
prescribing tablets.
(b) Injectable formulations
Some forms of methadone ampoules are now licensed
for opioid dependence treatment. The DH Clinical
Guidelines, and more recent NTA expert guidance on
injectable opiate prescribing, make clear that decisions
concerning initiation of injectable prescribing should
normally be made only after assessment by addiction
specialists (or by another doctor if they have sufficient
competence in this area). This could include some ‘general
practitioners with special interest’ if they have developed
the necessary expertise in the management of injectable
opiate prescribing.1
Ampoules are occasionally appropriate for some severely
opioid dependent patients, with a considerable injecting
history, who have not benefited from optimal oral
medication and for whom injecting itself has become a
strongly reinforced behaviour. Such patients who have
not succeeded with oral medication may obtain stability
on ampoules.37, 38 More research is needed and specialist
prescribing advice should be sought before injectable
methadone is even considered.
NB: Trials using injectable methadone and heroin under
supervised conditions are about to commence in the UK
(2005), which will help this discussion.39
Formulations:
 Methadone ampoules 10 mg/ml in 1 ml or 2 ml.
 Methadone ampoules 35 mg in 2 ml or 3.5 ml.
 Methadone ampoules 50 mg in 5 ml, 2 ml or 1 ml.
NB: The rest of this document will be referring to
methadone oral solution 1 mg/ml unless stated
otherwise.
Unwanted (or side) effects
Most unwanted effects of methadone are those associated
with all opioids, including nausea, vomiting, constipation
and drowsiness. Larger doses produce respiratory
depression and hypotension. Dry mouth, sweating,
headache and decreased libido may also occur.
Unwanted effects vary from individual to individual. Many
patients report a ‘clouding’ effect in the mind, which is
valued by some but not others. The common complaint
of sore leg muscles, which is sometimes described as
‘getting in your bones’, particularly in the 18 to 24 hour
period after dosing could indicate ‘breakthrough’
withdrawal effect from low plasma levels of methadone.
Such protracted withdrawal symptoms are commonly
experienced during suboptimal maintenance dosing or
when insufficient opioids are prescribed when a user is
undergoing detoxification from methadone.
Poor dental health is mainly related to poor dental hygiene
early in the patients using career, rather than the sugar
in the solution. A sugar-free formulation is no better for
the teeth and can cause abdominal symptoms, such as
flatulence, but less constipation.
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Duration of action:
 Low doses may exert clinical effects for only a few
hours, up to a maximum of 12 hours because receptor
occupancy will be minimal and plasma concentrations
sub-optimal.34
 Optimal doses usually between 24 to 36 hours.
Excretion:
 The products are mainly excreted as non-active
metabolites (and about 10% as unchanged
methadone) principally in the faeces and urine,
therefore urinalysis is only useful in confirming
methadone being taken, but not the dose.
Maintenance doses:
 While research evidence suggests that optimal
doses for most people lie between 60 to 120 mg,
some people will need more and some need less
due to a range of individual factors.1, 33
Equivalence:
 Direct equivalence to street heroin is difficult to
estimate as the purity of street heroin can vary (between
20 to 60%, but is usually around 50%). One gramme
of street heroin is usually roughly equivalent to
50 to 80 mg methadone.
 When comparing the equivalence of methadone to
injectable pharmaceutical diamorphine, half-lives must
be taken into consideration and it is not a linear
relationship, so it can vary from a methadone:
heroin ratio of 1:3 (or even 1:1 for very low doses)
to around 1:5 for high doses of diamorphine
(e.g. 120 mg methadone is equivalent to between 
360 and 600 mg of injectable diamorphine).
 Direct equivalence to buprenorphine is difficult to
estimate as the pharmacological properties of the two
agents are not identical (buprenorphine is a partial
agonist) and it is not a linear relationship.
 When comparing the efficacy of maintenance doses,
50 to 80 mg methadone is approximately as effective
as 12 to 16 mg buprenorphine in reducing heroin
use and retaining patients in treatment; 35
studies comparing optimal dose methadone to high
dose buprenorphine have yet to be undertaken.6
Tolerance:
 Develops at different speeds in different individuals
and can change in individuals over time.
 Develops differently for different effects e.g. quickly
for vomiting and not completely developed for
respiratory depression.
 With long-term use, and in response to continued
exposure of the brain to opiates, neuro-adaptation
occurs and involves changes in nerve and receptor
function.
 Level of heroin use is not the only factor in determining
the final methadone dose that will be required:
patients react to methadone differently: some will
need more, and some will need less than others
using the same amount of heroin.
 High dose heroin use does not always equate with
tolerance to methadone but there is a high degree
of cross-tolerance, so broadly speaking if your patient
is smoking a £10 bag of heroin a day, they won’t need
120 mg of methadone, and if they are injecting 2 g
of heroin they are unlikely to settle on 60 mg of
methadone.
 An intolerance to the pharmacological effects of
methadone oral solution (mixture) is rare but if
confirmed consider using sugar, chloroform or
colour-free formulations of methadone or another
medication (e.g. buprenorphine).
3. Types of methadone
(available in the UK)
(a) Oral formulations
1. Methadone oral solution (mixture) 1 mg/ml (green)
(oral solution is the European term now to
be used)
Methadone oral solution is licensed for the treatment
of opioid dependence in the UK. It contains 1 mg of
methadone in 1 ml of liquid and must be taken orally.
It is currently the drug of choice for substitute opioid
prescribing because:
 Its clinical effectiveness is supported by
extensive research.
 It alleviates opioid withdrawal symptoms.
 It is taken orally thus reducing the risk of injection.
 The dose can be carefully titrated to the optimal level.
 Blood levels can be kept very stable thus eliminating
post-dose euphoria and pre-dose withdrawal.
Methadone oral solution 1 mg/ml is the
formulation of choice in the management of
opioid substitution
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2. Methadone oral solution (concentrated mixture)
10 mg/ml (blue) and 20 mg/ml (brown)
Methadone oral solution also comes in more concentrated
forms, which are different strengths and vary in colour,
such as 10 mg /1 ml and 20 mg/1 ml. These formulations
are used in specialist settings for on-site dispensing.
Experienced practitioners working in primary care may
sometimes use these strengths for patients on high dose
methadone, to reduce the volume taken. However this
would normally be on a supervised consumption basis
as the higher concentration means there is a greater risk
of overdose should it be diverted onto the illicit market
and also because it is not viscous, unlike 1 mg/1ml
formulations and therefore is easier to inject.
Methadone linctus 1 mg/2.5 ml is used in palliative care for the control
of distressing cough in terminal lung cancer. It is not licensed for the
treatment of drug dependence.
3. Methadone tablets 5 mg
Methadone tablets are not licensed for the treatment of
drug dependence. The Advisory Council for the Misuse
of Drugs (ACMD) and the Clinical Guidelines advise
against the prescription of methadone tablets because
they can be injected and have a high street value.1, 36
Their prescribing in general practice is problematic
and not generally advised.
However, some long-term opioid dependent patients
prefer this formulation as tablets are easier to take, have
no unpleasant taste and are more convenient. They may
be justified for specific circumstances such as to prevent
vomiting in pregnancy; nausea due to chemotherapy,
during holidays abroad and where there is proven
intolerance to the mixture, if the prescriber has the level
of experience to prescribe them and has undertaken the
necessary precautions to ensure they are being taken
appropriately. Specialist advice should be taken before
prescribing tablets.
(b) Injectable formulations
Some forms of methadone ampoules are now licensed
for opioid dependence treatment. The DH Clinical
Guidelines, and more recent NTA expert guidance on
injectable opiate prescribing, make clear that decisions
concerning initiation of injectable prescribing should
normally be made only after assessment by addiction
specialists (or by another doctor if they have sufficient
competence in this area). This could include some ‘general
practitioners with special interest’ if they have developed
the necessary expertise in the management of injectable
opiate prescribing.1
Ampoules are occasionally appropriate for some severely
opioid dependent patients, with a considerable injecting
history, who have not benefited from optimal oral
medication and for whom injecting itself has become a
strongly reinforced behaviour. Such patients who have
not succeeded with oral medication may obtain stability
on ampoules.37, 38 More research is needed and specialist
prescribing advice should be sought before injectable
methadone is even considered.
NB: Trials using injectable methadone and heroin under
supervised conditions are about to commence in the UK
(2005), which will help this discussion.39
Formulations:
 Methadone ampoules 10 mg/ml in 1 ml or 2 ml.
 Methadone ampoules 35 mg in 2 ml or 3.5 ml.
 Methadone ampoules 50 mg in 5 ml, 2 ml or 1 ml.
NB: The rest of this document will be referring to
methadone oral solution 1 mg/ml unless stated
otherwise.
Unwanted (or side) effects
Most unwanted effects of methadone are those associated
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and drowsiness. Larger doses produce respiratory
depression and hypotension. Dry mouth, sweating,
headache and decreased libido may also occur.
Unwanted effects vary from individual to individual. Many
patients report a ‘clouding’ effect in the mind, which is
valued by some but not others. The common complaint
of sore leg muscles, which is sometimes described as
‘getting in your bones’, particularly in the 18 to 24 hour
period after dosing could indicate ‘breakthrough’
withdrawal effect from low plasma levels of methadone.
Such protracted withdrawal symptoms are commonly
experienced during suboptimal maintenance dosing or
when insufficient opioids are prescribed when a user is
undergoing detoxification from methadone.
Poor dental health is mainly related to poor dental hygiene
early in the patients using career, rather than the sugar
in the solution. A sugar-free formulation is no better for
the teeth and can cause abdominal symptoms, such as
flatulence, but less constipation.
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5. Choosing between maintenance
and detoxification
Choosing between maintenance and detoxification occurs
at many points during treatment, starting at the first
assessment and then at various points as appropriate.
Methadone can be used as a maintenance intervention
or as a detoxification agent, but is primarily now used as
a maintenance drug. Methadone is probably no longer
seen as the automatic first-line treatment for all patients
wishing to detoxify from heroin. Many find that
buprenorphine and lofexidine enable easier assisted
withdrawal, although the evidence is not overwhelming.35
It is important to consider the views of the patient if they
express a particular preference for any of these medications.
Maintenance is suitable for patients who want to stop
using illicit opioids but are unable to achieve abstinence
from all opioids at present. Prescribing is offered long-
term, at effective doses (usually between 60 to 120 mg
daily) individualised for each patient. The goal is harm
reduction and stabilisation of life-style. It may also be
prescribed on harm reduction grounds to those wanting
to reduce their consumption of illicit opioids. The most
powerful evidence base for methadone is for long-term
maintenance, with retention in treatment being an indicator
for better outcomes.9, 14  Enforced detoxification or
enforced dosage reduction has been shown to be
ineffective.28, 40
Detoxification can be attempted with highly motivated,
willing patients who wish to detoxify from all opioids.
However, the likelihood of success with methadone will
be reduced if the process is too rapid because of the
long-acting nature of the drug and its prolonged withdrawal
profile. It is important to assess whether the patient’s
circumstances are conducive to maintaining abstinence
and to advise on the timing of withdrawal accordingly.
Where circumstances are adverse, such as patients
who are homeless or awaiting court, a further period of
maintenance should be advised with support to achieve
appropriate stability and psychosocial change before
attempting detoxification.
There is a high relapse rate to heroin use and as such
detoxification should always be seen as a stage in the
process and not normally be seen as a stand-alone
treatment modality. It should never be imposed, particularly
since recent research has shown high mortality rates
among those detoxified.41  Detoxification should be followed
by a package of care, which can include: in and outpatient
rehabilitation, relapse prevention, support, self-help groups
and counselling. It is crucial to warn of the potential loss
of tolerance to opioids after a detoxification – relapsing to
heroin after a period of abstinence may be fatal. If patients
are moving from maintenance to detoxification they may
need to reduce their dose of methadone before transferring
to another drug such as buprenorphine. Lofexidine is still
sometimes used but the evidence for its effectiveness is
poor, especially used as a single agent. If in doubt seek
specialist advice.
6. Starting and titration of methadone
The purpose of titration is, in a safe manner, to establish
the patient as quickly as possible on a dose of methadone
that prevents opioid withdrawal, reduces the need to
take additional illicit opioids and keeps side-effects to a
minimum. Methadone dispensing and dosing should aim
to avoid the dangers of overdose and diversion. Insufficient
dosing may increase the risk of additional illicit drug use
and hence diminish treatment effectiveness and increase
accidental overdose risk.
If you are just beginning to care for opioid dependent
patients, a decision to start methadone for the first time
should be taken with advice from a specialist service or
from a colleague with a special interest.
If you want to start a patient on methadone it is not
difficult if done with care and remembering a few
basic principles:
 Methadone is excreted very slowly during the first
few days of treatment in methadone naïve individuals.
 It normally takes four to five days for plasma levels of
methadone to stabilise after dose commencement,
but it may take up to ten days to finally reach steady
state, which can increase the risk of overdose during
the early stages of treatment.
 Methadone should always be started on a low dose,
on supervised consumption and increased under
regular review until the correct stabilising dose for
each patient is reached.
 Don’t increase the dose without a practitioner seeing
the patient, which needs to be frequently, up to daily,
in the beginning.
 Risk of overdose is increased by using other drugs,
such as heroin, benzodiazepines and alcohol on top
of the methadone, with particular risk from injecting
drugs.
 A number of factors can alter methadone plasma
levels including gastric emptying, pregnancy and liver
metabolism, which can increase the risk of overdose.
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4. Indications, contraindications and precautions for use in primary care
Cautions
Extra caution should be exercised and benefits and risks assessed when prescribing methadone in the
following situations:
1. Concurrent use of other sedating drugs or medications. Methadone has been associated with sedation,
respiratory depression and coma when used in conjunction with central nervous system depressants such
as alcohol, benzodiazepines, barbiturates, neuroleptics and tricyclic anti-depressants. Monoamine oxidase
inhibitors (MAOIs) need to be avoided with methadone because of the potential risk of CNS hyperexcitation
(hyperthermia, delirium etc.) which has been noted with pethidine, but never, so far, with methadone. However
both alcohol and benzodiazepine use are common in those requesting methadone maintenance and should
not be regarded as absolute contraindications.
2. Medical conditions complicating opioid use. As with other opioids, methadone should be used cautiously
in individuals with recent head injury, acute abdominal conditions, or with severe respiratory, hepatic or
renal disease.
3. Patients suffering with chronic pain where opioid analgesia is indicated must be given appropriate doses of
additional opioid analgesia on top of that required for the management of dependence and so may need
increased doses of other opioid analgesics or methadone to get pain relief. Methadone 1 mg/ml is a weak
analgesic (also see section 9).
4. People with severe mental illness, with limited capacity to provide informed consent.
5. Medications that affect methadone levels. Some medications have a significant effect on methadone levels
e.g. rifampicin may require doubling or trebling of methadone dose and can precipitate severe withdrawal.
Methadone is excreted more rapidly by urine acidifiers e.g. ascorbic acid so can significantly reduce methadone
levels. Urine alkalinisers, such as sodium bicarbonate, reduce excretion so can increase methadone levels.
Assessment in primary care
A full assessment should be undertaken for all patients
in the usual way (see Clinical Guidelines1). It is important
to decide who is going to undertake the full assessment
and with whom that assessment will be shared in order
to avoid delay and unnecessary duplication. This needs
to include a full drug and alcohol history and planning
how to manage other drugs, alcohol and other health
needs such as hepatitis C.
Assessment should be an ongoing process and not a
barrier to treatment. Primary care is ideally suited to carry
out assessment as a patient can be seen and much
information gathered in several ten minute slots. This is
a difficult period for the patient in which they can easily
become distressed at unreasonable delays in providing
treatment. It is important to try to convey to the patient
that you are interested and willing to provide them with
medical care and treatment, and to explain to them
that you will try to make the assessment process as easy
and fast as possible while remaining safe and individually
appropriate. The information that is vital to obtain early
in the assessment is current and past drug use, previous
treatment and confirmation of opioid dependence.
 Data sent by data transfer or spreadsheets is collected
by the National Drug Treatment Monitoring System
(NDTMS), now run in England by the NTA, or by a
Drug Misuse Database form in Scotland (SMR24 form)
or Wales. The required data should always be
completed at assessment. These systems provide
valuable information on trends in the misuse of drugs.
Because the data is attributable through partial





 Allergy or proven intolerance to methadone.
Relative contraindications
 Severe liver disease, such as decompensated liver
disease. However, in many cases the benefits will
outweigh the risks with careful monitoring of liver
function.
 Under 16 years except on the advice of a specialist.
Always confirm opioid dependence before
starting methadone.
The risk of death from methadone is highest
during dose induction and after detoxification
or a period of abstinence.
Dose induction – ‘start low, go slow.’
Explain to the patient why you are being cautious
during dose induction.
Methadone saves lives but can also kill.
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Before starting methadone oral solution for the
first time:
 Confirm opioid dependence by history, examination
and toxicology.
 Check for objective signs of opioid dependence
including dilated pupils when the patient is
withdrawing and check for injection marks.
 Carry out body fluid toxicology (usually urine,
sometimes using oral fluid swabs) to confirm that
there are opioids in the system.
 Starting methadone on the first presentation is usually
not possible as results, other than on-site tests, often
take days to return. Use this time to continue the
assessment, provide harm reduction advice and ask
the patient to keep a drugs diary.
 Starting methadone is always important, occasionally
urgent and needs to be done as rapidly as it can
safely be done to avoid drop out from treatment.
 Supervised consumption should be used for the
titration period and at least the first three months.
 Never start methadone without evidence of
opioid dependence.
If opioid dependence is confirmed and a substitute
prescription of methadone oral solution is appropriate,
there are a number of different methods of initiating
methadone treatment. The ideal is as follows:
 Start with 10 to 30 mg methadone daily, based on
the assessment of the person’s opioid tolerance,
the frequency of use, the route of administration
and the use of other drugs such as benzodiazepines
and alcohol whilst remembering the long half-life
of methadone.
 If tolerance is low, or uncertain then starting doses
of 10 to 20 mg should be used.
 Deaths have occurred in individuals on levels as low
as 40 mg.
 When undertaking the induction in general practice,
it is preferable to see the patient frequently at the
outset, often daily, so that a series of further
assessments can be made to judge the cumulative
dosing effects. However this may be difficult to arrange
in many general practices and there are alternatives.
They are:
1. See the patient as frequently as possible, which
may be every few days and only increase the
dose then.
2. Ask for a drugs worker to come into the surgery
daily for the titration period.
3. Ask the local specialist service to undertake the
titration and take over the prescribing only once
the patient has been stabilised.
 A total increase for the first week in treatment
should not usually exceed 30 mg.
 Methadone can now be prescribed by qualified
‘supplementary prescribers’ (e.g. specialist pharmacists
or nurses) where this arrangement is agreed by the
doctor and the patient and detailed in the care plan.
At any dose, but particularly in the titration period, use
of alcohol, sedatives, particularly benzodiazepines, and/or
short-acting opioids (e.g., heroin, morphine,
dihydrocodeine, oxycodone) during induction significantly
increases the risk of overdose death.43   The patient must
be informed of these risks. Written patient information
leaflets on overdose risks are available. Commence dose
induction at the start of the week and see the patient
frequently during the dose induction period. The patient
should also be advised that it can take a few days to feel
comfortable on methadone, but this point will be reached.
It is quite common for illicit drug use to continue during
the early stages of treatment and patients should be
encouraged to refrain, as far as possible, from other illicit
drugs. During dose induction ensure that the patient
realises that they will get higher doses as necessary.
In one Australian study, 90% of those who died during
stabilisation were also using other drugs. The Australian
guidelines for induction of methadone suggest that it is
possible that being overcautious may paradoxically
increase the risk of a fatal overdose.44
Measures to reduce risks:
 Make sure the patient understands the long acting
nature of methadone and that it interacts with other
sedating drugs and alcohol.
 Arrange for the patient to receive methadone oral
solution by supervised consumption during the titration
and continue this for at least the first three months,
unless there is a valid reason to change.
 In view of the difficulty in calculating opioid tolerance,
the prudent methadone-dosing advice is to see the
patient frequently in the initial stages and to ‘start low
and go slow’ 45  and this can include observation one
hour after the first dose, where there are concerns
and this is feasible.
 Ask the patient what they have been using on top,
including alcohol and benzodiazepines, respond
accordingly by cautious gradual increase. When given
good information about safety many patients may be
able to reduce their other drug use when starting a
methadone prescription.
 Remember that alcohol use may not subside
automatically when methadone is prescribed in alcohol
dependent patients. Alcohol use should be assessed
specifically and help with alcohol withdrawal offered
to those who need it.
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Figure 1: Steady-state methadone concentration reached in four to five days.42
Illustrations adapted from ‘The Methadone Briefing’ (1996) – www.exchangesupplies.org






























0 12 24 36 60 7248
1st dose 2nd dose 3rd dose
Once-daily dosing of oral methadone at steady state
Once steady state is reached blood levels vary little but the patient may be aware






























4 5 6 7 8 9
C M Y CM MY CY CMY K
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Before starting methadone oral solution for the
first time:
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 Never start methadone without evidence of
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and the use of other drugs such as benzodiazepines
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They are:
1. See the patient as frequently as possible, which
may be every few days and only increase the
dose then.
2. Ask for a drugs worker to come into the surgery
daily for the titration period.
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 A total increase for the first week in treatment
should not usually exceed 30 mg.
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Guidance for the use of methadone for the treatment of opioid dependence in primary care9
Care must be taken, with consideration of reduced
methadone dose, if co-medication is discontinued.
While on methadone maintenance it is important that
there are regular reviews of treatment. In addition care
plans and goals should be reviewed at about three
monthly intervals.
Reviews include:
 Current drug use, including cannabis, and should
include checking for injecting sites.
 Current alcohol use, including a typical day.
 Update and check hepatitis and HIV status as
appropriate and complete any outstanding
vaccinations or screening required.
 Patients should be asked if they would like to make
any life changes and be supported to do so.
 They should be made aware of, and be able to access,
a range of local social and psychological services.
 Harm reduction advice needs to be given on any
other drug use, such as cocaine, alcohol and/or
benzodiazepines.
 The usual general medical services should always
be offered (including BP checks, smoking interventions,
contraception, smears, etc).
 Assessment of progress against goals, review and
renegotiation of care plan.
 Review of partner and any other family members,
particularly children.
NB: People on MMT have the same and some additional
health risks as any other patient and should have their
hypertension, diabetes or arthritis, for example, treated
and monitored in the same way against practice standards.
Methadone treatment research shows that in the UK
doses are on average less than 50 mg daily and only a
quarter of patients receive over 60 mg suggesting
inadequate dosing is common.2
Frequency of dosing for maintenance
 Methadone should be prescribed on a daily regimen
during the start of treatment.
 It should usually be dispensed daily under supervision
for at least the first three months and until there is
evidence that the patient’s health and lifestyle are
stabilising.
 Patients who have been stable on supervised
consumption for three months, who have no high-risk
drug use (e.g. ongoing use of heroin, other injecting
drug use, alcohol or benzodiazepines, frequent
intoxicated presentations, recent history of overdose)
may be considered for a daily take-home regimen.
 When stopping supervised consumption, the
methadone should normally be continued on a
daily collection basis for a period of time.
 When take-home doses are given, patients should be
warned of risks to children and non opioid-dependent
individuals of overdose and methadone should be
dispensed in child safety medicine bottles and stored
safely, preferably in a lockable box or cupboard.
Instalment prescribing
Instalment prescriptions should be written using blue
FP10 (MDA) prescription forms in England and Wales
and in Scotland using a GP10 (3). Prescriptions should
initially stipulate daily supervised consumption (see below)
and subsequently daily pick up. Frequency of dispensing
may be relaxed when patient has achieved stability,
although the dispensing interval should normally be
two or three times a week.
The importance of the pharmacist
Pharmacists are key individuals in the success of
methadone treatment. They will see the patient much
more often than the prescriber and can provide additional
important support. Close liaison with pharmacists should
be maintained. They should only dispense to the named
patient or a collector who has permission from the patient.
The doctor can also ask the pharmacist to report missed
doses and the doctor should inform the patient that this
will happen.
Ideally before issuing a prescription to a new patient,
the prescriber should make contact with the patient’s
nominated community pharmacy to confirm dispensing
arrangements.
Some pharmacists limit the number of people they are
able to take on and/or supervise in a day and some
shared care schemes work on the basis of available
supervised spaces per pharmacy.
Methadone is a Schedule 2 controlled drug therefore
clinicians are reminded that the Misuse of Drugs hand
writing requirements apply. There may be changes to
such requirements following consideration of the
Shipman Inquiry reports.
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 If people are drinking heavily then methadone may
 not be appropriate but if started, regular monitoring
is required.
 Sleep difficulties must be taken seriously and advice
about sleep hygiene should be given but avoid the
prescribing of sedatives. Insomnia associated with
heroin use often resolves when adequate doses of
methadone have been established.
 Advice about the risks of injecting should also be given.
7. Stabilisation of methadone dose
Stabilisation involves finding a suitable dose that keeps
the patient engaged in treatment without the need to
supplement with heroin and other drugs. After stabilisation,
the patient should feel comfortable throughout 24 hours
with no subjective or objective withdrawal before doses
and no sedation or euphoria after doses. The aim is to
enable the patient to put their dependence into the
background while tackling any associated health or social
goals. Attempts to keep the dose minimal, leaving the
patient with daily morning craving or disturbed sleep due
to falling serum levels, are counter-productive.
The large part of titration can be undertaken in two weeks.
Final dose stabilisation may take several weeks, but it is
important that this is achieved as quickly but as safely
as possible to prevent patient drop-out. After the first
two weeks, the patient should be seen every few days
to allow a steady state to be reached after a dose change.
The dose should increase by between 5 to 10 mg each
time, or up to a 30 mg total increase per week.1, 43
It will take between four to five (and up to ten) days to
reach steady state and to see the full consequences of
any dose increase or decrease. After the initial induction
(one to two weeks) the dose can be titrated more rapidly
to the therapeutic level.
Once at a steady-state level, methadone should be
present in sufficient concentration to maintain a therapeutic
‘comfort range’  throughout the dosing interval.46
There is no clear relationship between prior ‘heavy’
misuse of an opioid and the methadone dose ultimately
required for stabilisation.45
8. Maintenance methadone 
prescribing
Methadone maintenance is an effective, evidence based
treatment for opioid dependence. Outcomes for MMT
have been shown to be influenced greatly by how it is
delivered, and to be optimised by factors such as retaining
patients in treatment and prescribing at high enough
dosages.9, 14, 17, 18, 29
A recent Cochrane review confirms that doses of 60
to 100 mg daily are more effective than lower doses at
retaining patients in treatment and in reducing use of
heroin and cocaine while in drug treatment. The review
concludes that to find the optimal dose is a clinical ability,
but clinicians must consider these conclusions in treatment
strategies.48   The Clinical Guidelines state that on average
the dose range for maintenance, which shows the greatest
benefits for most patients is between 60 to 120 mg daily.1
A further Cochrane review considered the evidence of
buprenorphine maintenance versus placebo or methadone
maintenance for opioid dependence.49  The review
considered the outcomes of retention in treatment and
suppression of heroin use and concluded that methadone
at optimal doses was still the gold standard for
maintenance, although buprenorphine is also an effective
intervention for use in maintenance. It must also be
recognised that methadone is cheaper than equivalent
doses of buprenorphine. With the limited evidence of the
superiority of either medication for particular subgroups,
there is a strong argument that under the current pricing
arrangements, where there is no patient preference, or
other convincing clinical reason to favour buprenorphine,
methadone should be used as first line treatment for
opioid maintenance therapy.
Due to individual factors some patients require significantly
greater or lower doses for treatment success. If very high
doses are required a specialist referral may be required
which may include serum methadone level testing.
In particular, patients on enzyme inducing drugs that
increase methadone metabolism, such as rifampicin and
phenytoin, may require higher doses of methadone while
being co-prescribed with an enzyme inducing drug.
After stabilisation, the patient should feel
comfortable throughout 24 hours with no
subjective or objective withdrawal before doses
and no sedation or euphoria after doses.
Optimal outcomes with methadone
maintenance occur:
 When the dose is right, usually between
60 to 120 mg.
 Stable relationship with a key individual
e.g. GP or drug worker.
 When a range of non-pharmacological
interventions, such as counselling and
lifestyle support, are also available.
 Together these enhance the likelihood of
positive outcomes from methadone
maintenance treatment.9, 47
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Split doses33
There is evidence that some people in maintenance
treatment are more settled on split doses, particularly
during the third trimester of pregnancy. Others taking
enzyme-inducing medication, such as the anti-convulsant,
phenytoin for epilepsy, may experience a drop in methadone
plasma levels during the course of 24 hours, when once-
daily dosing is used. Patients receiving low doses of
methadone may not have stable blood levels of methadone
over 24 hours and may benefit from split dosing.
In some people, if they are entering into withdrawal before
their next dose, it may be more effective for them to split
the methadone dose than have it increased. This can
cause problems with supervised consumption, and if in
doubt expert advice should be sought. Symptoms of
overdose should be explained and the action required
in the event of an overdose.
Supervised consumption and take-home doses
Supervised consumption should be used as a therapeutic
tool at the beginning of treatment (and sometimes at
other times during treatment to check dose and tolerance).
It should continue where possible for a minimum of three
months, unless there is a good reason (such as work,
distance to the pharmacy, childcare responsibilities or
risk to confidentiality) and until the prescriber is satisfied
that the patient has both been stabilised on the correct
dose and is maintaining a reasonable level of adherence.
Before taking a patient off supervision a review should
be undertaken to confirm stability and discuss future
treatment. The pharmacist should be included in this
discussion. Only in rare situations is it appropriate to
continue supervised consumption indefinitely (e.g. severe
mental illness with risk of overdose, severe social instability,
and frequently missed doses). The introduction of take-
away doses, when appropriate, allows patients a more
normal life, and enhances the development of trust and
rapport. It also ensures that there is adequate capacity
to supervise new patients in local pharmacies.
There may be cases where supervised consumption may
not be appropriate and these should be resolved on an
individual basis. Supervised consumption can be
reinstated at any time if there are concerns. Ultimately
the need for supervision is a clinical decision, taken by
the doctor in conjunction with the patient, pharmacist
and others working the patient. Always make appropriate
arrangements with the pharmacist in advance of the
patient’s arrival.
There are benefits and problems with take-home doses.
Benefits include the practical and psychological
advantages of greater patient control. Problems include
the possibility of poor compliance and diversion on to
the illicit market.
Once the patient is sufficiently stable, less frequent
dispensing or take-home doses can be given. If giving
take-home doses, it may help to change the frequency
of pick up gradually, to three times weekly and then twice
weekly, assessing stability at each stage. It is rarely
appropriate to arrange for methadone to be dispensed
less frequently than this, unless exceptionally, for travel
or work.
Storage and safety at home
Once a patient is receiving take-home doses, then there
may be concerns about the amount of methadone that
is dispensed at once. There is no legal upper limit for this,
but caution and common sense should prevail. Different
decisions are appropriate for different patients, based
on their circumstances. Before take-home doses are
considered the prescriber needs to be assured that
supplies will be stored safely and away from children.
Safe storage should be discussed with all patients
particularly parents, by both clinician and dispensing
pharmacist. Symptoms of overdose should be explained
and the action required in the event of an overdose.
Screening
Can be done by i) urine ii) oral fluid swabs and
iii) hair analysis.
i) Urine testing
Confirming the presence of opioids in the urine is essential
at the start of treatment. Different drugs stay in the urine
for different lengths of time e.g. heroin 48 hours,
methadone on maintenance doses seven to nine days.
The frequency of urine testing, both to confirm the use
of methadone and assess other drug use (such as cocaine
and benzodiazepines) thereafter depends on clinical
progress. It should be undertaken at least every three
to four months and no less frequently than bi-annually.1
During induction and periods of instability or other drug
use, urine tests need to be done more frequently and
can help as a therapeutic tool.
Research studies have shown a high rate of concordance
between a patient’s report of their urine contents and
the lab result, where there is not a threat to the patient’s
treatment programme.9   False positives and negatives
do occur; especially with on-site urine testing and results
should always be used in conjunction with clinical signs,
such as signs of withdrawal, injecting sites etc. On-site
testing is non-specific and can only indicate the class of
drug in a non-quantitative way. Urine testing cannot alone
confirm heroin dependence. Use of over the counter or
prescribed medicines, e.g. cocodamol or codeine
phosphate, can also give positive results.
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Missed doses
Missed doses can lead to loss of tolerance and prescriber’s
need to be informed of any missed dose by the pharmacist.
It can take up to three days for the blood levels to return
to normal:
 If a patient on a daily dispensing regimen misses a
pickup from the pharmacy, the patient should return
the next day as usual for their next dose. The missed
dose should not be replaced.
 If doses are missed for more than three days then
treatment should be reviewed to discover how the
patient has managed without methadone and retitration
from a lower dose considered. This is due to the loss
of tolerance that may have occurred.
 If missed for five days or more a reassessment must
be undertaken and the titration period restarted from
the beginning.
 If a patient is picking up several days methadone at
one time and misses a pick-up, it is now possible to
issue a directive to the pharmacist enabling them to
dispense the medication on a subsequent day, minus
the missed dose. If this occurs more than once,
the patient should return to daily dispensing, probably
supervised.
 Lost or stolen prescriptions should rarely be replaced
and it may be useful to report this to the Primary
Care Trust.
 If this occurs it may be worth considering posting or
delivering prescriptions to the pharmacy.
 Patients who repeatedly miss doses should have
their treatment reviewed. If on less than daily dosing
the first step would be to revert to daily supervised
dispensing.
Continuing supervision:
 Occasionally patients do not keep appointments
with either their doctor or key worker.
 Maintaining the patient in treatment may be paramount
as long as some evidence of harm reduction can
be demonstrated.
 This can be achieved by keeping the patient on
observed consumption of their methadone and the
pharmacist may become the key worker.
Figure 2
Illustrations adapted from ‘The Methadone Briefing’ (1996) – www.exchangesupplies.org
Three day recovery to steady state from missed dose at day ten
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weekly, assessing stability at each stage. It is rarely
appropriate to arrange for methadone to be dispensed
less frequently than this, unless exceptionally, for travel
or work.
Storage and safety at home
Once a patient is receiving take-home doses, then there
may be concerns about the amount of methadone that
is dispensed at once. There is no legal upper limit for this,
but caution and common sense should prevail. Different
decisions are appropriate for different patients, based
on their circumstances. Before take-home doses are
considered the prescriber needs to be assured that
supplies will be stored safely and away from children.
Safe storage should be discussed with all patients
particularly parents, by both clinician and dispensing
pharmacist. Symptoms of overdose should be explained
and the action required in the event of an overdose.
Screening
Can be done by i) urine ii) oral fluid swabs and
iii) hair analysis.
i) Urine testing
Confirming the presence of opioids in the urine is essential
at the start of treatment. Different drugs stay in the urine
for different lengths of time e.g. heroin 48 hours,
methadone on maintenance doses seven to nine days.
The frequency of urine testing, both to confirm the use
of methadone and assess other drug use (such as cocaine
and benzodiazepines) thereafter depends on clinical
progress. It should be undertaken at least every three
to four months and no less frequently than bi-annually.1
During induction and periods of instability or other drug
use, urine tests need to be done more frequently and
can help as a therapeutic tool.
Research studies have shown a high rate of concordance
between a patient’s report of their urine contents and
the lab result, where there is not a threat to the patient’s
treatment programme.9   False positives and negatives
do occur; especially with on-site urine testing and results
should always be used in conjunction with clinical signs,
such as signs of withdrawal, injecting sites etc. On-site
testing is non-specific and can only indicate the class of
drug in a non-quantitative way. Urine testing cannot alone
confirm heroin dependence. Use of over the counter or
prescribed medicines, e.g. cocodamol or codeine
phosphate, can also give positive results.
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Missed doses
Missed doses can lead to loss of tolerance and prescriber’s
need to be informed of any missed dose by the pharmacist.
It can take up to three days for the blood levels to return
to normal:
 If a patient on a daily dispensing regimen misses a
pickup from the pharmacy, the patient should return
the next day as usual for their next dose. The missed
dose should not be replaced.
 If doses are missed for more than three days then
treatment should be reviewed to discover how the
patient has managed without methadone and retitration
from a lower dose considered. This is due to the loss
of tolerance that may have occurred.
 If missed for five days or more a reassessment must
be undertaken and the titration period restarted from
the beginning.
 If a patient is picking up several days methadone at
one time and misses a pick-up, it is now possible to
issue a directive to the pharmacist enabling them to
dispense the medication on a subsequent day, minus
the missed dose. If this occurs more than once,
the patient should return to daily dispensing, probably
supervised.
 Lost or stolen prescriptions should rarely be replaced
and it may be useful to report this to the Primary
Care Trust.
 If this occurs it may be worth considering posting or
delivering prescriptions to the pharmacy.
 Patients who repeatedly miss doses should have
their treatment reviewed. If on less than daily dosing
the first step would be to revert to daily supervised
dispensing.
Continuing supervision:
 Occasionally patients do not keep appointments
with either their doctor or key worker.
 Maintaining the patient in treatment may be paramount
as long as some evidence of harm reduction can
be demonstrated.
 This can be achieved by keeping the patient on
observed consumption of their methadone and the
pharmacist may become the key worker.
Figure 2
Illustrations adapted from ‘The Methadone Briefing’ (1996) – www.exchangesupplies.org
Three day recovery to steady state from missed dose at day ten
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(e.g. buprenorphine) and the use of non-pharmacological
treatment.
In some cases referral to a more specialised service may
be needed. This may also be related to unrecognised
mental health problems. Withdrawal of maintenance
treatment is associated with poor outcomes and should
be considered as a last resort. It should only happen if
it is determined through clinical observation that the
treatment is providing no benefit and there is not likelihood
of any benefit to the patient if it is continued or that it is
detrimental to the patient to continue.9  It may also be
helpful to discuss such cases with colleagues and
specialists before taking such actions as terminating
treatment.
9. Drug interactions
Oral methadone is generally very well tolerated with
minimal drug interactions but interactions are becoming
increasingly important as new drugs are developed and
more complicated regimens are used to treat chronic
diseases. The main drug interactions of methadone are
associated with its central nervous system (CNS)
depressant activity and liver metabolism. Deaths have
also been reported from interaction of methadone which
can prolong the QT interval and other drugs that do this
such as phenothiazines.
Benzodiazepines
Taking benzodiazepines with methadone may cause
additional CNS depression and result in enhanced sedative
effect. Large numbers of opioid drug users also use
benzodiazepines (between 40 to 90%). Deaths involving
methadone are frequently associated with concomitant
use of benzodiazepines and/or alcohol. 36   While it may
occasionally be advisable to prescribe benzodiazepines
with methadone, caution is recommended, and thorough
assessment and on-going review plans should be in
place. Benzodiazepines should usually be prescribed
on a short-term, reducing basis.
Alcohol
Alcohol intake may alter the metabolism of methadone,
increase CNS depression and result in serious respiratory
depression and hypotension. Alcohol is a high risk factor
for toxicity especially binge or high level dependent use.
In late stage alcohol misuse there may be impaired liver
function and reduced methadone metabolism, requiring
reduction in methadone dose. Alcohol use should be
assessed specifically and help with withdrawal offered
to those who need it.50
Other opioids
Mixing methadone with other opioid agonists or other
central nervous system depressants can be dangerous.
Caution is advised, as are thorough assessment and
review procedures.
Anti-depressants
Some anti-depressants, including tricyclic antidepressants,
should be prescribed with caution due to possible
enhanced sedation. Serotonin reuptake inhibitors (SSRIs)
theoretically raise serum methadone levels but do not
(except fluvoxamine) cause sedation. Monoamine oxidase
inhibitors (MAOIs) are now very rarely used and should
not be prescribed with methadone.
Cocaine
There are few reports of a significant interaction with
cocaine but cocaine does accelerate methadone
elimination. Cocaine is also associated with cardiac
rhythm disturbances and is best avoided when on
methadone. Risk of accidental overdose has recently
been linked to the use of these substances concomitantly.
Also cocaine is often included in poly-drug use which
increases problems.
Opioid antagonists and partial agonists
Opioid withdrawal syndrome is precipitated by the
use of naltrexone and naloxone and to a lesser extent
buprenorphine.
HIV medications
As with other opioids, patients on methadone being
treated with HIV combination therapies may require dose
levels to be adjusted but these adjustments are likely to
be minor and in keeping with titration principles, sufficient
to ensure patient comfort.51   It may be useful to offer
prescribing treatment in conjunction with a HIV specialist.
Enzyme induction by some HIV medications may
necessitate a higher dose of methadone due to increased
metabolism. With nevirapine, efavirenz, abacavir and
nelfinavir an increase in methadone could be needed
and zidovudine concentration and side-effects are
increased. See further guidance in the British National
Formulary and from HIV prescribing guidelines.
HCV medications
HCV medications such as pegylated interferon and
ribavirin are usually well tolerated by patients on
methadone. Sometimes side-effects can mimic opioid
withdrawal symptoms and methadone dose is
increased.52   Depression is a common side-effect of
hepatitis C combination therapy, as well as opioid
dependence so caution is required. Regular liver
function tests and full blood count are advised.
Tuberculosis treatment: rifampicin
Rifampicin reduces methadone levels by stimulating the
hepatic enzymes involved in methadone metabolism.
Cases of severe withdrawal have been reported.
Anticonvulsants
Phenytoin and carbamazepine cause a sharp decrease
in methadone due to enzyme induction.
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There is a widespread fear among patients that providing
a positive urine for non-prescribed drugs, including heroin,
may lead to the removal or reduction of the prescription
for methadone and even discharge from treatment.
However there is a strong consensus that it is inappropriate
and ineffective for a GP or others to ‘punish’ a patient
in this manner. Indeed an increase in methadone may
be needed if opioids are being used to treat early onset
withdrawal. In discussion with the patient, the results
should be used to inform decisions about the patient’s
response to the treatment. Even patients who continue
to use illicit drugs may benefit from harm reduction in
other areas. They should however be warned about
the risks of overdose.
A negative result for methadone should lead to further
testing and a review of treatment. In most laboratories
negative means below a threshold level rather than zero.
False negatives do occur in particular with low doses
and in pregnancy. If it seems that a patient has not been
taking their prescribed dose, then it is important to
re-assess, and if appropriate re-titrate or reduce the
prescribed dose and return to supervision.
Reasons for asking for a urine test could be:
 Initial confirmation of opioid use as part of the
assessment procedure.
 To confirm a patient’s suitability to end supervised
dispensing or need to return to it.
 To inform a planned discussion about a patient’s
progress in treatment.
 For court reports (after discussion with the patient
about this).
 At the request of the patient, e.g. to create a
usage history.
 To confirm that methadone is being taken (in the
first year every two to three months then every
three to four months moving to a minimum of every
six months).
 To gain more information about other drug use and
to monitor this.
 To confirm parents drug use in child protection cases.
 As part of comprehensive patient record keeping.
On-site urine testing
Most urinalysis procedures are carried out using gas
chromatography in specialist laboratories and there is a
therefore a delay in receiving a result. It can therefore be
very helpful to have a supply of on-site urine testing strips
that provide a basic guide to the drugs being used within
a couple of minutes. This is a screening tool and is not
confirmatory.
Providing urine specimens
It is rarely necessary to watch patients while they are
passing urine for analysis, as it is undignified for both
patient and professional and can give rise to mistrust
and suspicion. It should be done with the patient’s consent.
It is sometimes needed in court cases and specialist
advice should be sought if there is an indication for
observed urine.
There are several ways in which it is possible to be
reasonably confident that a sample has been freshly
passed – e.g. checking the temperature of the sample.
If there are any concerns or a court order requests these
then mouth swab tests should be used.
ii) Mouth swabs tests (oral mucosal transudate)
Mouth swab tests of oral fluid provide the same information
about recent drug use as testing urine. They are less
invasive, more convenient, and they preserve patient
dignity. However they can be more time consuming to
take and have a shorter detection window than urine
(about 24 to 48 hours for heroin compared to four
days for urine).
iii) Hair testing
Hair testing can provide a longer overview of drug use
over a period of months, with a quantitative result. It can
only however show an average drug use over each month.
It is expensive, and takes several weeks to obtain results
and tends to be used in the Criminal Justice System or
in child custody cases. Interpretation of the results is
complicated and may require specialist input.
Addressing continued heroin and
other drug use
Some patients may find it difficult to stabilise and be
maintained on methadone and this may be evidenced
by numerous phenomena including:
 Drug positive urine screens.
 Heavy alcohol usage.
 Frequently intoxicated presentations.
 Overdoses and presentions to Accident and
Emergency Departments.
 Frequently missed doses.
 Physical evidence such as fresh track marks.
 Mental deterioration, perhaps associated with
increased use of other drugs.
Such a pattern of events requires a review of treatment,
re-visiting the care plan and reviewing the objectives.
This may involve dose level adjustment, renegotiating
the short term treatment goals with the patient, altering
the dispensing regime, referring for psychosocial
interventions, increasing support and harm reduction
advice about alcohol, other drug use (such as cocaine and
benzodiazepines), utilising alternative pharmacotherapies
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(e.g. buprenorphine) and the use of non-pharmacological
treatment.
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treatment is providing no benefit and there is not likelihood
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more complicated regimens are used to treat chronic
diseases. The main drug interactions of methadone are
associated with its central nervous system (CNS)
depressant activity and liver metabolism. Deaths have
also been reported from interaction of methadone which
can prolong the QT interval and other drugs that do this
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occasionally be advisable to prescribe benzodiazepines
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function and reduced methadone metabolism, requiring
reduction in methadone dose. Alcohol use should be
assessed specifically and help with withdrawal offered
to those who need it.50
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Mixing methadone with other opioid agonists or other
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Caution is advised, as are thorough assessment and
review procedures.
Anti-depressants
Some anti-depressants, including tricyclic antidepressants,
should be prescribed with caution due to possible
enhanced sedation. Serotonin reuptake inhibitors (SSRIs)
theoretically raise serum methadone levels but do not
(except fluvoxamine) cause sedation. Monoamine oxidase
inhibitors (MAOIs) are now very rarely used and should
not be prescribed with methadone.
Cocaine
There are few reports of a significant interaction with
cocaine but cocaine does accelerate methadone
elimination. Cocaine is also associated with cardiac
rhythm disturbances and is best avoided when on
methadone. Risk of accidental overdose has recently
been linked to the use of these substances concomitantly.
Also cocaine is often included in poly-drug use which
increases problems.
Opioid antagonists and partial agonists
Opioid withdrawal syndrome is precipitated by the
use of naltrexone and naloxone and to a lesser extent
buprenorphine.
HIV medications
As with other opioids, patients on methadone being
treated with HIV combination therapies may require dose
levels to be adjusted but these adjustments are likely to
be minor and in keeping with titration principles, sufficient
to ensure patient comfort.51   It may be useful to offer
prescribing treatment in conjunction with a HIV specialist.
Enzyme induction by some HIV medications may
necessitate a higher dose of methadone due to increased
metabolism. With nevirapine, efavirenz, abacavir and
nelfinavir an increase in methadone could be needed
and zidovudine concentration and side-effects are
increased. See further guidance in the British National
Formulary and from HIV prescribing guidelines.
HCV medications
HCV medications such as pegylated interferon and
ribavirin are usually well tolerated by patients on
methadone. Sometimes side-effects can mimic opioid
withdrawal symptoms and methadone dose is
increased.52   Depression is a common side-effect of
hepatitis C combination therapy, as well as opioid
dependence so caution is required. Regular liver
function tests and full blood count are advised.
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Rifampicin reduces methadone levels by stimulating the
hepatic enzymes involved in methadone metabolism.
Cases of severe withdrawal have been reported.
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Phenytoin and carbamazepine cause a sharp decrease
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may lead to the removal or reduction of the prescription
for methadone and even discharge from treatment.
However there is a strong consensus that it is inappropriate
and ineffective for a GP or others to ‘punish’ a patient
in this manner. Indeed an increase in methadone may
be needed if opioids are being used to treat early onset
withdrawal. In discussion with the patient, the results
should be used to inform decisions about the patient’s
response to the treatment. Even patients who continue
to use illicit drugs may benefit from harm reduction in
other areas. They should however be warned about
the risks of overdose.
A negative result for methadone should lead to further
testing and a review of treatment. In most laboratories
negative means below a threshold level rather than zero.
False negatives do occur in particular with low doses
and in pregnancy. If it seems that a patient has not been
taking their prescribed dose, then it is important to
re-assess, and if appropriate re-titrate or reduce the
prescribed dose and return to supervision.
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progress in treatment.
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about this).
 At the request of the patient, e.g. to create a
usage history.
 To confirm that methadone is being taken (in the
first year every two to three months then every
three to four months moving to a minimum of every
six months).
 To gain more information about other drug use and
to monitor this.
 To confirm parents drug use in child protection cases.
 As part of comprehensive patient record keeping.
On-site urine testing
Most urinalysis procedures are carried out using gas
chromatography in specialist laboratories and there is a
therefore a delay in receiving a result. It can therefore be
very helpful to have a supply of on-site urine testing strips
that provide a basic guide to the drugs being used within
a couple of minutes. This is a screening tool and is not
confirmatory.
Providing urine specimens
It is rarely necessary to watch patients while they are
passing urine for analysis, as it is undignified for both
patient and professional and can give rise to mistrust
and suspicion. It should be done with the patient’s consent.
It is sometimes needed in court cases and specialist
advice should be sought if there is an indication for
observed urine.
There are several ways in which it is possible to be
reasonably confident that a sample has been freshly
passed – e.g. checking the temperature of the sample.
If there are any concerns or a court order requests these
then mouth swab tests should be used.
ii) Mouth swabs tests (oral mucosal transudate)
Mouth swab tests of oral fluid provide the same information
about recent drug use as testing urine. They are less
invasive, more convenient, and they preserve patient
dignity. However they can be more time consuming to
take and have a shorter detection window than urine
(about 24 to 48 hours for heroin compared to four
days for urine).
iii) Hair testing
Hair testing can provide a longer overview of drug use
over a period of months, with a quantitative result. It can
only however show an average drug use over each month.
It is expensive, and takes several weeks to obtain results
and tends to be used in the Criminal Justice System or
in child custody cases. Interpretation of the results is
complicated and may require specialist input.
Addressing continued heroin and
other drug use
Some patients may find it difficult to stabilise and be
maintained on methadone and this may be evidenced
by numerous phenomena including:
 Drug positive urine screens.
 Heavy alcohol usage.
 Frequently intoxicated presentations.
 Overdoses and presentions to Accident and
Emergency Departments.
 Frequently missed doses.
 Physical evidence such as fresh track marks.
 Mental deterioration, perhaps associated with
increased use of other drugs.
Such a pattern of events requires a review of treatment,
re-visiting the care plan and reviewing the objectives.
This may involve dose level adjustment, renegotiating
the short term treatment goals with the patient, altering
the dispensing regime, referring for psychosocial
interventions, increasing support and harm reduction
advice about alcohol, other drug use (such as cocaine and
benzodiazepines), utilising alternative pharmacotherapies
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11. Special Groups
Pregnancy
Methadone treatment is recommended for heroin use in
pregnancy as, compared to illicit drug use, it appears to
benefit fetal growth and survival and there is less risk of
prematurity. These improved outcomes may however be
related to improved antenatal care and improved diet
and not to methadone alone.53  Women attending
treatment services usually have better antenatal care and
better health even if they continue to use illicit drugs.54
The rate of stillbirth is higher in illicit heroin users
(5% compared to 1%) but there is no increase in fetal
abnormalities in opioid users compared to non-users.
How best to use methadone in pregnancy is still a matter
of debate. Methadone stability is recommended rather
than dose reduction due to the high risk of relapse to
illicit opioid use and possible loss of stability. Pregnant
patients should be maintained on the dose that they are
comfortable on and sufficient to get the positive benefits
of MMT.
Abrupt withdrawal of methadone is probably best avoided
due to the possible risks to the pregnancy such as:
miscarriage, fetal distress and premature labour. The
evidence that detoxification causes intrauterine death is
very weak.55  There are a few isolated case studies but
there is not a good link between detoxification and fetal
death. One study showed increased catecholamines in
liquor following untreated detoxification. However there
is biochemical evidence suggesting stress effect on baby
but not evidence that baby was actually stressed to
significant extent. There is little data to prove or disprove
the effects of detoxification but results from a service in
Glasgow suggest detoxification is acceptably safe at any
speed at any stage of pregnancy and this is much stronger
than evidence to the contrary.56
The important conclusion that should be recognised is
that whether or not the woman undergoes methadone
reduction or detoxification, or what stage of pregnancy,
or what speed she does this at, should be dictated by
what is appropriate for her circumstances/wishes/ability
to cope etc and not only by any consideration about
what is or isn’t safe for the fetus. Also we shouldn’t
impose limitations on management plans that women
choose on the basis of unsubstantiated risks. It is also
important to continue the current dose of methadone
if the woman is arrested or admitted to hospital to avoid
any problems and to prevent stability being lost.
There is some suggestion that an increase in dose may
be needed in the third trimester to maintain pre-pregnancy
blood levels due to the increase in blood volume
(haemodilution effect) in pregnancy, increased liver
metabolism and increased glomerular filtration rate.
But again there is little evidence to support this. There
is evidence of reduced serum levels but this is not
necessarily indicative of less effect.
A maternity drug service in Glasgow has found that most
women manage greatest reductions in the third trimester
and other centres following their advice are finding the
same thing.57  But always check for signs of withdrawal
and if detected, make a small (2 to 5 mg) increase in
methadone dose. Pregnant women may sometimes
benefit from splitting their dose of methadone if signs of
withdrawal occur. It is useful to have close liaison between
prescriber and pharmacist during the early months of
pregnancy when morning sickness may be an issue.
This may cause vomiting of methadone soon after it is
swallowed and it is essential to ensure quick replacement
of prescriptions and it may be appropriate to prescribe
a safe anti-emetic.
The primary aim should be to stabilise the patient and
prevent injecting. Stabilisation helps to engage the person
with antenatal care. Adequate postnatal preparation can
then be planned to manage any withdrawal effects
observed in the infant. No long-term consequences of
opioid withdrawal have been observed in infants born to
opioid using women.
Neonates
At all doses there is a risk of neonatal abstinence syndrome
(NAS), which is a generalized disorder presenting a clinical
picture of CNS hyperirritability, high pitched cry, rapid
breathing, gastrointestinal dysfunction, respiratory distress,
hungry but ineffective sucking and excessive wakefulness.
It varies with individuals and is not influenced by maternal
age or the sex of the baby. Symptoms are less likely to
be severe in preterm infants, possibly due to immaturity
of the neurological system, and are more severe if the
baby is otherwise unwell or irritable for example in
association with birth asphyxia, infection etc. While there
is not a linear relationship between severity of neonatal
withdrawal symptoms and maternal methadone dose in
the individual case there is an overall correlation with
evidence that the higher the maternal methadone dose
the greater the likelihood and likely severity of neonatal
withdrawal symptoms.58   Informed consent to treatment
should always be documented in the patient’s notes.
(But note if the mother withheld consent and the baby
is judged to need treatment this could be a child
protection issue).
Symptoms generally begin during the first 24 hours (heroin
and benzodiazepines only) after birth but can be delayed
by up to five or more days.58   Some have reported a delay
in the onset of symptoms for as long as seven to ten days.
Methadone tends to cause a delay in the onset of neonatal
withdrawal symptoms when compared to heroin. While
up to 90% of newborns exposed to opioids during fetal
life have some symptoms, only 50 to 75% will require
treatment. However the proportion that needs treatment
is different in different populations and for example will be
higher in areas with higher overall neonatal morbidity,
e.g. in Glasgow where there is very severe socio-economic
deprivation. Newborns exposed to methadone are more
likely to experience symptoms and more often require
treatment than those exposed to heroin.
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10. Methadone and other
medical conditions
1. Blood-borne viruses
 Methadone is safe to use when the patient is hepatitis
B or C positive or HIV positive (for interactions with
specific medications see above), but LFTs should be
monitored, particularly if the patients clinical condition
changes.
2. Dual diagnosis (co-morbidity of substance
misuse and psychiatric illness)
 Methadone can be used in severe, moderate and mild
psychiatric illness if the patient is opioid dependent
and understands the treatment.
 About a third of opioid users suffer from mild to severe
mental health problems, including anxiety and
depression.
 A minority (about 10%) have severe enduring mental
health problems that usually require joint working with
psychiatric services.
 Entry into methadone treatment has a significant
positive effect on their psychological well-being.
 A proportion of opioid users presenting at services
have suicidal or self-harm risks.
 The risks of accidental or deliberate overdose, and
of intimidation or exploitation should be carefully
considered when deciding dispensing arrangements.
 Many of the patients with mental health problems
will require joint working with psychiatric services
and others.
 Drug interactions with psychotropics should be
remembered.3
3. Chronic and acute pain
 Opioids are strong analgesics and some patients
begin their use of opioids to help chronic pain.
 If pain is present when they commence methadone,
a larger dose can be used to manage the addiction
as well as treat the pain. If being used as analgesia
it is recommended to split the dose to three or four
times a day.
 A patient currently maintained on methadone requiring
analgesia for the relief of pain, will need at least the
usual dose and frequency of analgesia, and may
require greater amounts due to opioid tolerance.
Pain relief should be titrated against pain and balanced
against observed toxicity signs e.g. sedation.
 Methadone 1 mg/ml is a weak analgesic but increasing
the methadone can be tried as a pain relief.
 Morphine is useful for analgesia, but if the patient is
on 100 mg methadone already, significant doses of
morphine may be needed to ensure analgesic effect.
 NSAIDs e.g. diclofenac can be useful.
 Paracetamol is first line for mild to moderate pain.
4. Liver disease
 Methadone is metabolised by the liver and its activity
may be increased and/or prolonged in individuals
with impaired hepatic function.
 It appears safe in patients with HCV as severe liver
disease does not increase peak serum methadone
levels, despite a prolongation of the apparent
terminal half life.52
 If there is abnormal liver function (as evidenced by
lowered serum albumin or total protein) or evidence
of cirrhosis, proceed with caution and seek
specialist advice.
 Reduced platelet count is the best indicator of cirrhosis.
Altered liver function tests are not well correlated with
the presence or absence of cirrhosis.
 In patients with advanced liver disease the risks from
controlled methadone are insignificant compared to
the risks from street drugs and therefore we should
encourage people to use it.
5. Fertility
 Methadone treatment may restore fertility in women
who were using heroin, so contraceptive advice
should also be given.
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what is appropriate for her circumstances/wishes/ability
to cope etc and not only by any consideration about
what is or isn’t safe for the fetus. Also we shouldn’t
impose limitations on management plans that women
choose on the basis of unsubstantiated risks. It is also
important to continue the current dose of methadone
if the woman is arrested or admitted to hospital to avoid
any problems and to prevent stability being lost.
There is some suggestion that an increase in dose may
be needed in the third trimester to maintain pre-pregnancy
blood levels due to the increase in blood volume
(haemodilution effect) in pregnancy, increased liver
metabolism and increased glomerular filtration rate.
But again there is little evidence to support this. There
is evidence of reduced serum levels but this is not
necessarily indicative of less effect.
A maternity drug service in Glasgow has found that most
women manage greatest reductions in the third trimester
and other centres following their advice are finding the
same thing.57  But always check for signs of withdrawal
and if detected, make a small (2 to 5 mg) increase in
methadone dose. Pregnant women may sometimes
benefit from splitting their dose of methadone if signs of
withdrawal occur. It is useful to have close liaison between
prescriber and pharmacist during the early months of
pregnancy when morning sickness may be an issue.
This may cause vomiting of methadone soon after it is
swallowed and it is essential to ensure quick replacement
of prescriptions and it may be appropriate to prescribe
a safe anti-emetic.
The primary aim should be to stabilise the patient and
prevent injecting. Stabilisation helps to engage the person
with antenatal care. Adequate postnatal preparation can
then be planned to manage any withdrawal effects
observed in the infant. No long-term consequences of
opioid withdrawal have been observed in infants born to
opioid using women.
Neonates
At all doses there is a risk of neonatal abstinence syndrome
(NAS), which is a generalized disorder presenting a clinical
picture of CNS hyperirritability, high pitched cry, rapid
breathing, gastrointestinal dysfunction, respiratory distress,
hungry but ineffective sucking and excessive wakefulness.
It varies with individuals and is not influenced by maternal
age or the sex of the baby. Symptoms are less likely to
be severe in preterm infants, possibly due to immaturity
of the neurological system, and are more severe if the
baby is otherwise unwell or irritable for example in
association with birth asphyxia, infection etc. While there
is not a linear relationship between severity of neonatal
withdrawal symptoms and maternal methadone dose in
the individual case there is an overall correlation with
evidence that the higher the maternal methadone dose
the greater the likelihood and likely severity of neonatal
withdrawal symptoms.58   Informed consent to treatment
should always be documented in the patient’s notes.
(But note if the mother withheld consent and the baby
is judged to need treatment this could be a child
protection issue).
Symptoms generally begin during the first 24 hours (heroin
and benzodiazepines only) after birth but can be delayed
by up to five or more days.58   Some have reported a delay
in the onset of symptoms for as long as seven to ten days.
Methadone tends to cause a delay in the onset of neonatal
withdrawal symptoms when compared to heroin. While
up to 90% of newborns exposed to opioids during fetal
life have some symptoms, only 50 to 75% will require
treatment. However the proportion that needs treatment
is different in different populations and for example will be
higher in areas with higher overall neonatal morbidity,
e.g. in Glasgow where there is very severe socio-economic
deprivation. Newborns exposed to methadone are more
likely to experience symptoms and more often require
treatment than those exposed to heroin.
Guidance for the use of methadone for the treatment of opioid dependence in primary care 16
10. Methadone and other
medical conditions
1. Blood-borne viruses
 Methadone is safe to use when the patient is hepatitis
B or C positive or HIV positive (for interactions with
specific medications see above), but LFTs should be
monitored, particularly if the patients clinical condition
changes.
2. Dual diagnosis (co-morbidity of substance
misuse and psychiatric illness)
 Methadone can be used in severe, moderate and mild
psychiatric illness if the patient is opioid dependent
and understands the treatment.
 About a third of opioid users suffer from mild to severe
mental health problems, including anxiety and
depression.
 A minority (about 10%) have severe enduring mental
health problems that usually require joint working with
psychiatric services.
 Entry into methadone treatment has a significant
positive effect on their psychological well-being.
 A proportion of opioid users presenting at services
have suicidal or self-harm risks.
 The risks of accidental or deliberate overdose, and
of intimidation or exploitation should be carefully
considered when deciding dispensing arrangements.
 Many of the patients with mental health problems
will require joint working with psychiatric services
and others.
 Drug interactions with psychotropics should be
remembered.3
3. Chronic and acute pain
 Opioids are strong analgesics and some patients
begin their use of opioids to help chronic pain.
 If pain is present when they commence methadone,
a larger dose can be used to manage the addiction
as well as treat the pain. If being used as analgesia
it is recommended to split the dose to three or four
times a day.
 A patient currently maintained on methadone requiring
analgesia for the relief of pain, will need at least the
usual dose and frequency of analgesia, and may
require greater amounts due to opioid tolerance.
Pain relief should be titrated against pain and balanced
against observed toxicity signs e.g. sedation.
 Methadone 1 mg/ml is a weak analgesic but increasing
the methadone can be tried as a pain relief.
 Morphine is useful for analgesia, but if the patient is
on 100 mg methadone already, significant doses of
morphine may be needed to ensure analgesic effect.
 NSAIDs e.g. diclofenac can be useful.
 Paracetamol is first line for mild to moderate pain.
4. Liver disease
 Methadone is metabolised by the liver and its activity
may be increased and/or prolonged in individuals
with impaired hepatic function.
 It appears safe in patients with HCV as severe liver
disease does not increase peak serum methadone
levels, despite a prolongation of the apparent
terminal half life.52
 If there is abnormal liver function (as evidenced by
lowered serum albumin or total protein) or evidence
of cirrhosis, proceed with caution and seek
specialist advice.
 Reduced platelet count is the best indicator of cirrhosis.
Altered liver function tests are not well correlated with
the presence or absence of cirrhosis.
 In patients with advanced liver disease the risks from
controlled methadone are insignificant compared to
the risks from street drugs and therefore we should
encourage people to use it.
5. Fertility
 Methadone treatment may restore fertility in women
who were using heroin, so contraceptive advice
should also be given.
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If the patient is admitted via Emergency Departments in
working hours and after proper assessment, checking
their dose with the drug user, confirming opioid use via
on-site urine test, checking with the community pharmacist
and confirmation with the prescriber methadone treatment
may be continued only if the prescription is daily dispensed
and preferably supervised. Out of hours, if the prescription
cannot be verified, if there is any doubt that the person
is taking the total prescribed dose or the hospital cannot
confirm the dose then titration should be undertaken.
Local guidelines should be in place. If not then the local
shared care monitoring group may wish to assist in the
drawing up of local guidelines.
12. Detoxification from
methadone maintenance
The patient needs to make an active decision to transfer
from maintenance to detoxification. The clinician and
patient should be clear about the distinction and together
they should ensure the patient is actively choosing to
undergo detoxification. It is important that the patient
has the resources and support to be able to maintain
abstinence. Advice on the timing of withdrawal should
be offered accordingly. Where circumstances are adverse,
a further period of maintenance should be advised with
support to achieve appropriate psychosocial change.
Detoxification is more likely to be completed in a residential
setting and should always be part of a package which
will include relapse prevention, counselling, rehabilitation
and support.
If the patient wishes, methadone can be prescribed in
reducing doses as agreed between doctor and patient
until final detoxification is achieved. This slow reduction
of methadone is not necessarily the first-line method of
opioid detoxification, but some patients may prefer it.
If this is the patients preferred method then it is preferable
to remain on an optimal dose until the patient has stopped
using heroin completely and then reduce the dose at
their own pace. Reductions of no more than 5 mg weekly
are recommended. It is also possible to reduce the
methadone dose to 30 mg and then transfer to
buprenorphine which is reportedly easier to withdraw
from.6  Specialist advice can also assist in the timing and
choice of method of detoxification.
Enforced reduction in doses of methadone is still a
common treatment modality in the UK despite having no
supporting evidence base and mounting evidence against
its effectiveness.28
13. Shared care
Treatment of drug-using patients is multi-facetted and
often requires a multidisciplinary response. Most drug-
using patients now use a combination of drugs (poly-
drug use). The treatment of the other drug and alcohol
problems must not be forgotten in the case of this group
of patients. Methadone prescribing is only a part of
treatment and should be undertaken in a planned manner
in collaboration with the patient and other individuals and
agencies, such as a primary care drug worker and
community pharmacist.
Prescribing should not be undertaken in isolation and
working within a local support structure for primary
care is important from both clinical and medico-legal
perspectives.
There is now consensus in the field that care planning
in primary care contributes to common goal setting in
the treatment of the drug user. It also mitigates against
professional isolation. There is a wide variety of models
of care planning and indeed models of shared care
working. Regardless of setting the support for both the
professional and the user who takes methadone should
be consistent.
Many shared care schemes are set up to manage opioid
users and rarely meet the needs of poly-drug users.
Schemes should be encouraged to meet the needs of
the individual, not a specific drug.7
Supplementary prescribers may play an increasing role
in shared care.
14. Methadone and driving
Applicants or drivers complying fully with a supervised
oral methadone maintenance programme may be licensed,
subject to favourable assessment and normally an annual
medical review (DVLA, 2004). However, patients will be
subject to revocation of their licence for a minimum
12 month period where it can be shown that there has
been persistent use of, or dependency on, heroin;
morphine; methadone and/or cocaine. Once the 12
month period is completed the applicant will be assessed
as to whether they can be licensed whilst on a methadone
maintenance programme.
It is the patient’s responsibility to inform the DVLA, and
it is the doctor’s responsibility to inform the patient of this.
It is important to record that this advice has been given
to the patient.
The DVLA and GMC also state that if doctors are aware
that patients continue to drive in a dangerous way, then
they should first press such patients more forcibly not to
drive. If the patient continues to drive, doctors (at their
discretion) should break confidentiality, inform DVLA and
inform the patient that they are doing so. This is a very
difficult area of practice. Doctors may not want to endanger
the relationship with patients, but it would certainly be
both tragic, as well as highly problematic, for any doctor,
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Women using drugs or delivering a baby who experiences
withdrawals may suffer severe guilt feelings and they will
need help and counselling to address these. Caring for
babies that are unwell, including babies with neonatal
withdrawal symptoms, can also be more demanding and
drug-using mothers whose babies develop withdrawals
may need additional parenting support.
Breast-feeding
Breast-feeding is to be encouraged in all drug-using
women, unless they are HIV positive, not only because
of the usual advantages but also because some
methadone does pass across to the breast milk and this
in turn will reduce the severity of any withdrawals the
baby is experiencing. Moreover use of tobacco, opiates
and benzodiazepines is associated with an increased
risk of sudden infant death which is lower among
breast-fed babies.
Parents of young children
Parental drug use can have serious implications to a
child at all stages and must be carefully assessed
throughout care. As drug use is a chronic relapsing
condition this is an on-going process. Hidden Harm,
the report of the Advisory Council for the Misuse of Drugs
on responding to the needs of children of problem drug
users, found that daily heroin use, daily alcohol use,
regular stimulant use, unstable accommodation and
criminal justice involvement are risk indicators for children
of drug-using parents.27   But Hidden Harm also concluded
that effective treatment of the parent can have major
benefits for the child.27
The children’s needs are paramount but drug use per se
is not a reason to instigate child protection procedures.
Parenting skills may need to be assessed and appropriate
support offered where indicated. GPs and others in
primary care have an important role in the assessment,
monitoring and care of children in families where there
is parental drug use. It is essential to use a multi-disciplinary
approach with good communication between agencies
when looking after parents of young children where drug
use is an issue.
Particular attention on safe storage needs to be given to
parents on methadone.
Young people (under 18 years)
Methadone is not usually first line treatment for young
opioid using patients (under the age of 18) as their drug
use is often short-term and there is less tolerance.
Detoxification, with buprenorphine, may be considered
as first line plus more specialist services should be involved.
Practitioners working in primary care should not work in
isolation with children under 13 years and need to involve
specialist practitioners in their care.
Black and minority ethnic groups
Heroin users from BME communities can be marginalised
in treatment. It is crucial to develop services to meet the
needs of diverse communities.59   There is also a need
to understand how a combination of factors that
characterise the lives of many BME people, in particular
risk factors that revolve around social exclusion and
deprivation, mean that the context within which drug use
exists provides an environment in which it can be
particularly problematic.
Methadone treatment in primary care is the same for any
patient, but primary care services treating patients from
different cultural backgrounds need to be aware of this
issue and how it may impact upon the user, staff and
the service itself. It is not an issue that can be adequately
addressed unless there is understanding and services
will need to give consideration to service accessibility,
appropriateness of service and potential barriers to
service utilisation.
People in prison
People in prison should have access to the same
treatment options as in the community, including
methadone maintenance and detoxification options.43
Staff need to have relevant training. A national system
in the UK to accommodate universal access to substitution
treatment in prisons is currently being introduced.
Methadone maintenance has recently become available
at many prisons throughout the world, but usually with
a maximum dose of 40 or 45 mg per day, the argument
being that these doses are satisfactory in the context of
low availability of illicit drugs.60  However, the only serious
research on the subject comes from New South Wales,
where they have shown that methadone maintenance is
effective in bringing hard-to-reach drug-users into
treatment, reducing overdose rate during and after
imprisonment, reducing injecting and blood-borne virus
infection, and preventing recidivism.61  The dose range
was similar to that used in the community, because initial
studies indicated that benefits only occurred when daily
doses were above 60 mg/day.62  Studies are being
planned in this country, but until they take place, it is
probably safest to assume that the effective dose range
in prison is the same as elsewhere. Currently this issue
will need to be determined locally by practitioners working
in prison health.
Also staff need to remember the dangers of detoxification
in prison, with increase overdose risk on release.63
People admitted to hospital
Patients are often frightened when entering hospital and
the GP can help to improve this difficult process by writing
a letter with the dose of methadone clearly stated and
phoning the admitting doctor to reinforce this.
Detoxification should always be seen as a stage
in the process, never as a stand alone treatment
and never imposed. It should always be
supported by after-care because of the high risk
of relapse, the loss of tolerance and the risk of
overdose and death.41
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If the patient is admitted via Emergency Departments in
working hours and after proper assessment, checking
their dose with the drug user, confirming opioid use via
on-site urine test, checking with the community pharmacist
and confirmation with the prescriber methadone treatment
may be continued only if the prescription is daily dispensed
and preferably supervised. Out of hours, if the prescription
cannot be verified, if there is any doubt that the person
is taking the total prescribed dose or the hospital cannot
confirm the dose then titration should be undertaken.
Local guidelines should be in place. If not then the local
shared care monitoring group may wish to assist in the
drawing up of local guidelines.
12. Detoxification from
methadone maintenance
The patient needs to make an active decision to transfer
from maintenance to detoxification. The clinician and
patient should be clear about the distinction and together
they should ensure the patient is actively choosing to
undergo detoxification. It is important that the patient
has the resources and support to be able to maintain
abstinence. Advice on the timing of withdrawal should
be offered accordingly. Where circumstances are adverse,
a further period of maintenance should be advised with
support to achieve appropriate psychosocial change.
Detoxification is more likely to be completed in a residential
setting and should always be part of a package which
will include relapse prevention, counselling, rehabilitation
and support.
If the patient wishes, methadone can be prescribed in
reducing doses as agreed between doctor and patient
until final detoxification is achieved. This slow reduction
of methadone is not necessarily the first-line method of
opioid detoxification, but some patients may prefer it.
If this is the patients preferred method then it is preferable
to remain on an optimal dose until the patient has stopped
using heroin completely and then reduce the dose at
their own pace. Reductions of no more than 5 mg weekly
are recommended. It is also possible to reduce the
methadone dose to 30 mg and then transfer to
buprenorphine which is reportedly easier to withdraw
from.6  Specialist advice can also assist in the timing and
choice of method of detoxification.
Enforced reduction in doses of methadone is still a
common treatment modality in the UK despite having no
supporting evidence base and mounting evidence against
its effectiveness.28
13. Shared care
Treatment of drug-using patients is multi-facetted and
often requires a multidisciplinary response. Most drug-
using patients now use a combination of drugs (poly-
drug use). The treatment of the other drug and alcohol
problems must not be forgotten in the case of this group
of patients. Methadone prescribing is only a part of
treatment and should be undertaken in a planned manner
in collaboration with the patient and other individuals and
agencies, such as a primary care drug worker and
community pharmacist.
Prescribing should not be undertaken in isolation and
working within a local support structure for primary
care is important from both clinical and medico-legal
perspectives.
There is now consensus in the field that care planning
in primary care contributes to common goal setting in
the treatment of the drug user. It also mitigates against
professional isolation. There is a wide variety of models
of care planning and indeed models of shared care
working. Regardless of setting the support for both the
professional and the user who takes methadone should
be consistent.
Many shared care schemes are set up to manage opioid
users and rarely meet the needs of poly-drug users.
Schemes should be encouraged to meet the needs of
the individual, not a specific drug.7
Supplementary prescribers may play an increasing role
in shared care.
14. Methadone and driving
Applicants or drivers complying fully with a supervised
oral methadone maintenance programme may be licensed,
subject to favourable assessment and normally an annual
medical review (DVLA, 2004). However, patients will be
subject to revocation of their licence for a minimum
12 month period where it can be shown that there has
been persistent use of, or dependency on, heroin;
morphine; methadone and/or cocaine. Once the 12
month period is completed the applicant will be assessed
as to whether they can be licensed whilst on a methadone
maintenance programme.
It is the patient’s responsibility to inform the DVLA, and
it is the doctor’s responsibility to inform the patient of this.
It is important to record that this advice has been given
to the patient.
The DVLA and GMC also state that if doctors are aware
that patients continue to drive in a dangerous way, then
they should first press such patients more forcibly not to
drive. If the patient continues to drive, doctors (at their
discretion) should break confidentiality, inform DVLA and
inform the patient that they are doing so. This is a very
difficult area of practice. Doctors may not want to endanger
the relationship with patients, but it would certainly be
both tragic, as well as highly problematic, for any doctor,
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Women using drugs or delivering a baby who experiences
withdrawals may suffer severe guilt feelings and they will
need help and counselling to address these. Caring for
babies that are unwell, including babies with neonatal
withdrawal symptoms, can also be more demanding and
drug-using mothers whose babies develop withdrawals
may need additional parenting support.
Breast-feeding
Breast-feeding is to be encouraged in all drug-using
women, unless they are HIV positive, not only because
of the usual advantages but also because some
methadone does pass across to the breast milk and this
in turn will reduce the severity of any withdrawals the
baby is experiencing. Moreover use of tobacco, opiates
and benzodiazepines is associated with an increased
risk of sudden infant death which is lower among
breast-fed babies.
Parents of young children
Parental drug use can have serious implications to a
child at all stages and must be carefully assessed
throughout care. As drug use is a chronic relapsing
condition this is an on-going process. Hidden Harm,
the report of the Advisory Council for the Misuse of Drugs
on responding to the needs of children of problem drug
users, found that daily heroin use, daily alcohol use,
regular stimulant use, unstable accommodation and
criminal justice involvement are risk indicators for children
of drug-using parents.27   But Hidden Harm also concluded
that effective treatment of the parent can have major
benefits for the child.27
The children’s needs are paramount but drug use per se
is not a reason to instigate child protection procedures.
Parenting skills may need to be assessed and appropriate
support offered where indicated. GPs and others in
primary care have an important role in the assessment,
monitoring and care of children in families where there
is parental drug use. It is essential to use a multi-disciplinary
approach with good communication between agencies
when looking after parents of young children where drug
use is an issue.
Particular attention on safe storage needs to be given to
parents on methadone.
Young people (under 18 years)
Methadone is not usually first line treatment for young
opioid using patients (under the age of 18) as their drug
use is often short-term and there is less tolerance.
Detoxification, with buprenorphine, may be considered
as first line plus more specialist services should be involved.
Practitioners working in primary care should not work in
isolation with children under 13 years and need to involve
specialist practitioners in their care.
Black and minority ethnic groups
Heroin users from BME communities can be marginalised
in treatment. It is crucial to develop services to meet the
needs of diverse communities.59   There is also a need
to understand how a combination of factors that
characterise the lives of many BME people, in particular
risk factors that revolve around social exclusion and
deprivation, mean that the context within which drug use
exists provides an environment in which it can be
particularly problematic.
Methadone treatment in primary care is the same for any
patient, but primary care services treating patients from
different cultural backgrounds need to be aware of this
issue and how it may impact upon the user, staff and
the service itself. It is not an issue that can be adequately
addressed unless there is understanding and services
will need to give consideration to service accessibility,
appropriateness of service and potential barriers to
service utilisation.
People in prison
People in prison should have access to the same
treatment options as in the community, including
methadone maintenance and detoxification options.43
Staff need to have relevant training. A national system
in the UK to accommodate universal access to substitution
treatment in prisons is currently being introduced.
Methadone maintenance has recently become available
at many prisons throughout the world, but usually with
a maximum dose of 40 or 45 mg per day, the argument
being that these doses are satisfactory in the context of
low availability of illicit drugs.60  However, the only serious
research on the subject comes from New South Wales,
where they have shown that methadone maintenance is
effective in bringing hard-to-reach drug-users into
treatment, reducing overdose rate during and after
imprisonment, reducing injecting and blood-borne virus
infection, and preventing recidivism.61  The dose range
was similar to that used in the community, because initial
studies indicated that benefits only occurred when daily
doses were above 60 mg/day.62  Studies are being
planned in this country, but until they take place, it is
probably safest to assume that the effective dose range
in prison is the same as elsewhere. Currently this issue
will need to be determined locally by practitioners working
in prison health.
Also staff need to remember the dangers of detoxification
in prison, with increase overdose risk on release.63
People admitted to hospital
Patients are often frightened when entering hospital and
the GP can help to improve this difficult process by writing
a letter with the dose of methadone clearly stated and
phoning the admitting doctor to reinforce this.
Detoxification should always be seen as a stage
in the process, never as a stand alone treatment
and never imposed. It should always be
supported by after-care because of the high risk
of relapse, the loss of tolerance and the risk of
overdose and death.41
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19. Handwriting exemptions
(NB likely to change post Shipman Inquiry)
If treating ‘or likely to treat’ 10 or more patients for drug
dependence using a blue FP10 (MDA) form (in England
and Wales) then a doctor can apply for an exemption
from handwriting requirements from the Home Office.
Forms are available from the Home Office on request.
This is probably going to change because of the overall
increase in the number of computer generated
prescriptions.
There are a number of rubber stamps and computer
packages, which can be used to help the speed and
accuracy of filling in the prescriptions. Computer generated
prescriptions or stamps are permissible if a doctor has
a hand writing exemption but the date and signature still
need to be hand written. This requirement may change
following consideration of the recommendations of the
Shipman Inquiry.
20. Further reading
a) Methadone Maintenance Treatment and Other Opioid
Replacement Therapies. Edited by Jeff Ward,
Richard Mattick and Wayne Hall.
Harwood Academic Publishers, 1998.
b) Care of drug users in general practice: a harm
reduction approach. Second edition.
Edited by Berry Beaumont. Radcliffe Publishing, 2004.
c) Drug Misuse and Dependence: Guidelines on
Clinical Management. DoH, 1999.
d) RCGP Guide to The Management of Substance
Misuse in Primary care. Edited by Clare Gerada.
e) Methadone Guidelines. Edited by Annette Verster
and Ernst Buning Eurometh, June 2000.
f) Methadone Matters: evolving community methadone
treatment of opiate addiction. Edited by Gillian Tober
and John Strang, Martin Dunitz Publishing,
London, 2003.
g) Methadone treatment for opioid dependence.
Edited by EC Strain and ML Stitzer, The John Hopkins
University Press, Baltimore and London, 1999.
h) Drug Misuse and Community Pharmacy.
Edited by Janie Sheridan and John Strang,
Taylor and Francis, 2003.
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if patients hurt or kill people while driving in a manner
already known to be unsafe.
More information is available on the DVLA website:
www.dvla.gov.uk
15. Holiday prescribing
Larger instalments of methadone may be needed for
patients going on holiday. If leaving the country a home
office export license is required for total amounts over
500 mg, which is usually granted. A doctor needs to write
on behalf of the patient to apply for this (see appendix 3).
This does not automatically allow importation to the
country being visited and some countries do not allow
importation. Patients will need also to check the
requirements of the country they are entering by contacting
the embassy. A prescriber’s note outlining the prescription
is also advisable for anyone taking methadone out of the
country. It is advisable to ask the pharmacist to supply
measured daily doses in plastic bottles to minimise the
risk of breakage and spillage.
For patients travelling in the UK it may be safer to provide
their usual FP10 (MDA) to take to their destination.
Phoning the local drug service may be helpful with
arranging local dispensing chemists.
For more details see appendix 3.
16. Patient education
The properties of methadone as a full opiate agonist
mean that it carries the same risks as other opiate agonists.
It is therefore important that patients are given full
information about its action and effects. This should
include effects and unwanted effects, how to start, the
risk of potentiation if used with other sedative substances
such as alcohol and benzodiazepines, the risks from loss
of tolerance post-detoxification or withdrawal (especially
following physical illness or imprisonment), risks of using
with cocaine and information regarding safety in pregnancy.
Contraceptive advice needs to be discussed with all
potentially sexually active drug-using patients, including
the use of condoms for protection against sexually
transmitted infections.
Advice about fertility returning to normal soon after
initiation of treatment, probably related to improved
general health and weight gain, should be given to all
women commencing treatment. Consideration should
be given to providing patients with written as well as
verbal information about treatment issues. Some high
quality patient information booklets exist about
methadone treatment e.g. The Methadone Handbook.64
Appendix 1 is a leaflet that can be photocopied and
given to patients.
17. Training
The most important skills needed for managing drug-
using patients in general practice are the skills doctors
use every day with every patient.
Practitioners should only prescribe and treat at levels of
practice with which they feel competent and for which
they have received adequate training. There is a full range
of national training opportunities, organised by the Royal
College of General Practitioners (RCGP) that can be
accessed by GPs, pharmacists and other members of
the primary health care team, including Part 1 and
Part 2 of the RCGP Certificate in Drug Misuse. There
are also many other both national and local training
opportunities. The minimum training requirement for
prescribers should be the RCGP Certificate Part 1 or
equivalent.
18. Methadone, the Misuse of Drugs
Act 1971, the Misuse of Drugs
Regulations 2001 and cost
Methadone is defined by the Misuse of Drugs Act 1971
as a class A drug regarding its illicit use. As a medicine
it falls within Schedule 2 of the Misuse of Drugs regulations
2001 (as compared to buprenorphine which falls within
schedule 3). Consequently it attracts a slightly higher
dispensing fee than buprenorphine although the drug
itself is cheaper. Both require compliance with the MDA
handwriting regulations.
For the latest price of methadone, see the monthly drug
tariff for prices. The approximate cost for 500 ml (1 mg/ml)
ingredient costs is £7.59p (source British National
Formulary, 49, March 2005).
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19. Handwriting exemptions
(NB likely to change post Shipman Inquiry)
If treating ‘or likely to treat’ 10 or more patients for drug
dependence using a blue FP10 (MDA) form (in England
and Wales) then a doctor can apply for an exemption
from handwriting requirements from the Home Office.
Forms are available from the Home Office on request.
This is probably going to change because of the overall
increase in the number of computer generated
prescriptions.
There are a number of rubber stamps and computer
packages, which can be used to help the speed and
accuracy of filling in the prescriptions. Computer generated
prescriptions or stamps are permissible if a doctor has
a hand writing exemption but the date and signature still
need to be hand written. This requirement may change
following consideration of the recommendations of the
Shipman Inquiry.
20. Further reading
a) Methadone Maintenance Treatment and Other Opioid
Replacement Therapies. Edited by Jeff Ward,
Richard Mattick and Wayne Hall.
Harwood Academic Publishers, 1998.
b) Care of drug users in general practice: a harm
reduction approach. Second edition.
Edited by Berry Beaumont. Radcliffe Publishing, 2004.
c) Drug Misuse and Dependence: Guidelines on
Clinical Management. DoH, 1999.
d) RCGP Guide to The Management of Substance
Misuse in Primary care. Edited by Clare Gerada.
e) Methadone Guidelines. Edited by Annette Verster
and Ernst Buning Eurometh, June 2000.
f) Methadone Matters: evolving community methadone
treatment of opiate addiction. Edited by Gillian Tober
and John Strang, Martin Dunitz Publishing,
London, 2003.
g) Methadone treatment for opioid dependence.
Edited by EC Strain and ML Stitzer, The John Hopkins
University Press, Baltimore and London, 1999.
h) Drug Misuse and Community Pharmacy.
Edited by Janie Sheridan and John Strang,
Taylor and Francis, 2003.
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if patients hurt or kill people while driving in a manner
already known to be unsafe.
More information is available on the DVLA website:
www.dvla.gov.uk
15. Holiday prescribing
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Appendix 1
Methadone in primary care: patient information leaflet
Important points
 When starting methadone, your prescriber has to weigh up a number of factors to get to the right dose
for you. This process is called ‘titration’, and it means assessing the safest amount of methadone to
control your withdrawal symptoms. There is a serious risk of overdose if this is not done with care.
You can help by not using other drugs during this period, or telling the doctor if you are uncomfortable.
 This is the beginning of a process that can take a few weeks and the dose should continue to be increased
until you feel comfortable and don’t need to use heroin on top. For most people, this is usually when the
dose is between 60 to 120 mg of methadone.
You have been prescribed methadone by your general practitioner (GP) or prescriber. This leaflet aims to
give you some information about the drug and how it can help you. There are patient booklets available that
can give you more details. So ask your GP or drug worker if they can provide you with one. A booklet is no
substitute to talking to your doctor, nurse, drug worker or pharmacist – so, if there is something you need
more information about, just ask. They will be happy to try and answer your questions and if they can’t
answer your question they may know someone who can. There are many places on the web where you can
get more information and we mention a few at the end of this leaflet.
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What is methadone?
Methadone is the name given to the medication you have
been prescribed. Methadone is a long-acting opioid drug
which acts in your body for between 24 and 36 hours.
It has a depressant effect on your body and breathing,
which is similar (though not identical) to heroin, which is
also an opioid. It stabilises you and your body by
preventing withdrawal symptoms and it ensures you can
feel well without using heroin. If you are taking the right
dose of methadone, you won’t feel much from heroin if
you use on top, and this helps you to reduce your use
of street drugs.
Why methadone?
Methadone is licensed by the Department of Health as
an effective treatment for opioid dependence. There is
also a lot of medical research that says it is effective and
helpful for many people.
Why has it been difficult to get methadone?
Until recently there was a lot of confusion among doctors
about providing methadone treatment. Some believed
it should only be used for a short time; others believed
it had no place in treatment. This led to situations where
many drug users had bad experiences of methadone
treatment, and this left them with a bad impression.
Fortunately in most places, this controversy has now
ended. It changed because of the sheer volume of
research showing that methadone can be very helpful
to opiate dependent drug users. And in the last few years,
people getting methadone have been working with
treatment providers, the National Treatment Agency,
and others to challenge poor practices that are not friendly
to patients.
For many people, methadone is very effective. It isn’t
right for everyone, which is why it is important to talk
about other alternative treatments with your doctor and
counsellor. But if you haven’t had methadone from a
doctor trained in how best to use it, and who wants to
help drug users, then it might be time to give it a go and
see if it can help you.
So what does methadone do?
It stabilises the changes that happen in the brain when
you become dependent on opiates. Your brain has natural
opiates called endorphins. When you become dependent
on heroin, this replaces the body’s endorphins. But if you
stop taking heroin, it takes time for the brain to register
this and bring back the natural endorphins. It is this lack
of opiates (no heroin, no endorphins) which causes
withdrawal symptoms.
Sometimes called clucking, or getting sick, it is an
unpleasant experience, particularly without any help
to reduce some of the worst symptoms.
If you are dependent and taking short acting opiates like
heroin, you will get sick about six to eight hours after you
last use. But as methadone is long-acting and works for
between 24 and 36 hours it will take 24 hours or more
without methadone before you start to get sick.
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Appendix 1
Methadone in primary care: patient information leaflet
Important points
 When starting methadone, your prescriber has to weigh up a number of factors to get to the right dose
for you. This process is called ‘titration’, and it means assessing the safest amount of methadone to
control your withdrawal symptoms. There is a serious risk of overdose if this is not done with care.
You can help by not using other drugs during this period, or telling the doctor if you are uncomfortable.
 This is the beginning of a process that can take a few weeks and the dose should continue to be increased
until you feel comfortable and don’t need to use heroin on top. For most people, this is usually when the
dose is between 60 to 120 mg of methadone.
You have been prescribed methadone by your general practitioner (GP) or prescriber. This leaflet aims to
give you some information about the drug and how it can help you. There are patient booklets available that
can give you more details. So ask your GP or drug worker if they can provide you with one. A booklet is no
substitute to talking to your doctor, nurse, drug worker or pharmacist – so, if there is something you need
more information about, just ask. They will be happy to try and answer your questions and if they can’t
answer your question they may know someone who can. There are many places on the web where you can
get more information and we mention a few at the end of this leaflet.
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What is methadone?
Methadone is the name given to the medication you have
been prescribed. Methadone is a long-acting opioid drug
which acts in your body for between 24 and 36 hours.
It has a depressant effect on your body and breathing,
which is similar (though not identical) to heroin, which is
also an opioid. It stabilises you and your body by
preventing withdrawal symptoms and it ensures you can
feel well without using heroin. If you are taking the right
dose of methadone, you won’t feel much from heroin if
you use on top, and this helps you to reduce your use
of street drugs.
Why methadone?
Methadone is licensed by the Department of Health as
an effective treatment for opioid dependence. There is
also a lot of medical research that says it is effective and
helpful for many people.
Why has it been difficult to get methadone?
Until recently there was a lot of confusion among doctors
about providing methadone treatment. Some believed
it should only be used for a short time; others believed
it had no place in treatment. This led to situations where
many drug users had bad experiences of methadone
treatment, and this left them with a bad impression.
Fortunately in most places, this controversy has now
ended. It changed because of the sheer volume of
research showing that methadone can be very helpful
to opiate dependent drug users. And in the last few years,
people getting methadone have been working with
treatment providers, the National Treatment Agency,
and others to challenge poor practices that are not friendly
to patients.
For many people, methadone is very effective. It isn’t
right for everyone, which is why it is important to talk
about other alternative treatments with your doctor and
counsellor. But if you haven’t had methadone from a
doctor trained in how best to use it, and who wants to
help drug users, then it might be time to give it a go and
see if it can help you.
So what does methadone do?
It stabilises the changes that happen in the brain when
you become dependent on opiates. Your brain has natural
opiates called endorphins. When you become dependent
on heroin, this replaces the body’s endorphins. But if you
stop taking heroin, it takes time for the brain to register
this and bring back the natural endorphins. It is this lack
of opiates (no heroin, no endorphins) which causes
withdrawal symptoms.
Sometimes called clucking, or getting sick, it is an
unpleasant experience, particularly without any help
to reduce some of the worst symptoms.
If you are dependent and taking short acting opiates like
heroin, you will get sick about six to eight hours after you
last use. But as methadone is long-acting and works for
between 24 and 36 hours it will take 24 hours or more
without methadone before you start to get sick.
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What should I do to keep other people
and myself safe?
Methadone is dangerous to people who are not used
to it. The risks are greater if methadone is taken in
combination with other depressant drugs. This is
particularly true of drugs called benzodiazepines (‘benzos’
such as diazepam [Valium], temazepam, nitrazepam
[Mogadon], or Rohypnol) that are commonly prescribed
for sleeping, stress, or anxiety problems. However, it is
also true for some other drugs that are sometimes
prescribed by doctors e.g. antidepressants like Prozac.
Please tell your GP if you are taking any other drugs or
prescribed medication.
People often forget that alcohol is a drug too. Like
benzodiazepines and the other drugs mentioned, alcohol
can be dangerous when taken with methadone. So, if
you do have a drink, be very careful not to overdo it.
You should not drink more than three units of alcohol
(one and half pints of beer or three glasses of wine) for
a man or more than two units (pint of beer or two glasses
of wine) for a woman per day.
Because opiates can harm and even kill people who
are not used to taking them, it is important that no one
else takes or gets access to your medication. Like all
medicines, but especially with these drugs, it is very
important that methadone is stored safely out of the
reach of children. A very small dose of methadone can
kill a child.
What will happen if I use heroin ‘on top’?
Methadone, in adequate doses, reduces any effect from
heroin so you may find yourself disappointed. However,
you can still overdose, so if you do use heroin ‘on top’,
remember to take great care, as there is a risk of overdose
and always use a clean needle and syringe. Talk to your
doctor – he or she wants to help you manage this.
What will happen if I use cocaine ‘on top’?
This can increase your risk of overdose and is best
avoided. If this is not possible, use with at least one other
person present and be aware how to manage overdose.
What happens if I get pregnant while
on methadone?
Methadone is not known to harm your baby during
pregnancy. But if you are taking it at the time of the
delivery the baby may experience some withdrawal
symptoms. These are uncomfortable and if necessary
can be treated but they are not dangerous to the baby.
Talk to your GP, prescriber or primary care team member
as soon as you find out that you are pregnant, and they
will give you the best advice on what your options are.
Don’t stop your methadone as this will be the worst
option for the baby.
Can I drive on methadone?
You need to inform the DLVA that you are receiving a
prescription of methadone. You can then drive for personal
reasons (not for work) while taking oral methadone after
undergoing a short independent medical examination,
which will include a urine screen for drugs. The licence
will be issued for one year at a time and will need to be
supported by a favourable medical report from your
doctor. It is your responsibility to do this, not the doctor
or the drug worker. If you do not notify the DVLA, continue
to drive and your doctor feels you are posing a risk to
others on the road they now have to inform the DLVA.
Also if you get stopped by the police or have an accident
and haven’t notified the DVLA, your insurance is likely to
be invalid and you could be heavily fined or sent to jail.
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What is the right dose of methadone for you?
The right dose depends very much on you as an individual.
It is partly dependent on your size and age, and to a
lesser extent, the amount of heroin or other opioid you
are using. The length of time you have used for can also
affect the dose you should take. Research shows that
the best doses for maintenance are between 60 to
120 mg. The aim is for you to feel comfortable and
well without withdrawal symptoms.
What does methadone maintenance mean?
It means taking the same amount of medication without
reducing it. Staying on a regular dose helps you reduce
and often stop using heroin or other opiate drugs. It used
to be that people were expected to come off methadone
after a short time but this led to many people returning
to injecting street drugs who had been doing well on
methadone. Research suggests that some people need
to keep taking methadone over a long period of time to
stay well, perhaps for the foreseeable future. However,
others do stop taking methadone at some point without
returning to using. Keep an open mind and listen to your
own feelings. No one should force you to stop methadone
if it is clearly helping you to manage your condition.
Why do people say it is more addictive and
more difficult to get off than heroin?
All opiates are difficult to get off. Because methadone
is an opiate that has a long duration of action, it takes
longer to come out of the body than other short acting
opiates. So it takes longer for the withdrawals to start to
ease. This is actually why methadone is an excellent drug
for maintenance treatment – it lasts a very long time.
You get optimum benefit when your body enters a ‘steady
state’ where the amount of methadone in your blood
remains constant. This happens in a few days when you
take the same amount of methadone regularly at around
the same time.
Also, people feel less scared nowadays of staying on
methadone if they need it. When people were expected
to stop, sometimes without agreement, people felt
vulnerable. Some refused to take methadone because
they were scared of the possibility of it being cut off.
Now the days when patients were forced to come off
their methadone have largely ended.
How do I take methadone?
Methadone commonly comes in a liquid form, which is
called methadone mixture or more recently methadone
oral solution. It should only be swallowed (taken orally).
How will methadone make me feel?
It can take an hour for you to start to feel the effects of
the methadone you have taken, especially if you took
your methadone after a meal. You should feel your body
start to relax from any withdrawal-related tension, and
you should start to feel comfortable without feeling drowsy
or confused. The opiate sensation that you get from
taking methadone is unlikely to be as strong as the high
you felt when you were using heroin, but as your dose
is adjusted you should start to feel comfortable and well
and without any feelings of withdrawal. After a few days,
you should feel less and less craving for heroin. You will
feel a lot healthier if you can stop using illicit heroin and
try to manage with just the methadone.
The maximum effect of methadone mixture can take well
over an hour to feel. The high that you get while you are
taking methadone is not as strong as the high you felt
when you were using heroin, but you will not go into
withdrawal. It feels different from heroin, but after a few
days you should feel less and less craving for heroin.
Are there any serious side-effects to
methadone treatment?
There are very few side-effects to methadone, and all
of them can be managed with help and advice. Some
people may find they perspire more, particularly
around the face. This usually gets better with time.
Constipation is also a possible side-effect, as the medicine
acts directly on the gut to slow down the passage of
food through the body. Your doctor can give you more
advice about this. It is important to drink adequate
amounts of water during the day and to eat fruit and
vegetables containing dietary fibre.
Methadone does not cause any direct damage to your
bones or teeth. The stories you may have heard that
methadone ‘gets into the bones’ are not true.
Will I have to take my dose in front of
the pharmacist?
Taking medication at the chemist in front of a pharmacist
is called ‘supervised consumption.’ Most people will have
to take it under supervised consumption to start with as
it is the best way of ensuring you are taking your
methadone safely and correctly. If you can show your
doctor that you are stabilised on methadone (i.e. you are
not using heroin or other drugs bought illicitly) there is
no reason why you should not ask to have take-home
doses of methadone. This should be possible after a
period of months, unless there are good reasons such
as working or child care for it to be less. Ultimately
however, this is a decision that only your GP or prescriber
can make.
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Because opiates can harm and even kill people who
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important that methadone is stored safely out of the
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on methadone?
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symptoms. These are uncomfortable and if necessary
can be treated but they are not dangerous to the baby.
Talk to your GP, prescriber or primary care team member
as soon as you find out that you are pregnant, and they
will give you the best advice on what your options are.
Don’t stop your methadone as this will be the worst
option for the baby.
Can I drive on methadone?
You need to inform the DLVA that you are receiving a
prescription of methadone. You can then drive for personal
reasons (not for work) while taking oral methadone after
undergoing a short independent medical examination,
which will include a urine screen for drugs. The licence
will be issued for one year at a time and will need to be
supported by a favourable medical report from your
doctor. It is your responsibility to do this, not the doctor
or the drug worker. If you do not notify the DVLA, continue
to drive and your doctor feels you are posing a risk to
others on the road they now have to inform the DLVA.
Also if you get stopped by the police or have an accident
and haven’t notified the DVLA, your insurance is likely to
be invalid and you could be heavily fined or sent to jail.
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What is the right dose of methadone for you?
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It is partly dependent on your size and age, and to a
lesser extent, the amount of heroin or other opioid you
are using. The length of time you have used for can also
affect the dose you should take. Research shows that
the best doses for maintenance are between 60 to
120 mg. The aim is for you to feel comfortable and
well without withdrawal symptoms.
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It means taking the same amount of medication without
reducing it. Staying on a regular dose helps you reduce
and often stop using heroin or other opiate drugs. It used
to be that people were expected to come off methadone
after a short time but this led to many people returning
to injecting street drugs who had been doing well on
methadone. Research suggests that some people need
to keep taking methadone over a long period of time to
stay well, perhaps for the foreseeable future. However,
others do stop taking methadone at some point without
returning to using. Keep an open mind and listen to your
own feelings. No one should force you to stop methadone
if it is clearly helping you to manage your condition.
Why do people say it is more addictive and
more difficult to get off than heroin?
All opiates are difficult to get off. Because methadone
is an opiate that has a long duration of action, it takes
longer to come out of the body than other short acting
opiates. So it takes longer for the withdrawals to start to
ease. This is actually why methadone is an excellent drug
for maintenance treatment – it lasts a very long time.
You get optimum benefit when your body enters a ‘steady
state’ where the amount of methadone in your blood
remains constant. This happens in a few days when you
take the same amount of methadone regularly at around
the same time.
Also, people feel less scared nowadays of staying on
methadone if they need it. When people were expected
to stop, sometimes without agreement, people felt
vulnerable. Some refused to take methadone because
they were scared of the possibility of it being cut off.
Now the days when patients were forced to come off
their methadone have largely ended.
How do I take methadone?
Methadone commonly comes in a liquid form, which is
called methadone mixture or more recently methadone
oral solution. It should only be swallowed (taken orally).
How will methadone make me feel?
It can take an hour for you to start to feel the effects of
the methadone you have taken, especially if you took
your methadone after a meal. You should feel your body
start to relax from any withdrawal-related tension, and
you should start to feel comfortable without feeling drowsy
or confused. The opiate sensation that you get from
taking methadone is unlikely to be as strong as the high
you felt when you were using heroin, but as your dose
is adjusted you should start to feel comfortable and well
and without any feelings of withdrawal. After a few days,
you should feel less and less craving for heroin. You will
feel a lot healthier if you can stop using illicit heroin and
try to manage with just the methadone.
The maximum effect of methadone mixture can take well
over an hour to feel. The high that you get while you are
taking methadone is not as strong as the high you felt
when you were using heroin, but you will not go into
withdrawal. It feels different from heroin, but after a few
days you should feel less and less craving for heroin.
Are there any serious side-effects to
methadone treatment?
There are very few side-effects to methadone, and all
of them can be managed with help and advice. Some
people may find they perspire more, particularly
around the face. This usually gets better with time.
Constipation is also a possible side-effect, as the medicine
acts directly on the gut to slow down the passage of
food through the body. Your doctor can give you more
advice about this. It is important to drink adequate
amounts of water during the day and to eat fruit and
vegetables containing dietary fibre.
Methadone does not cause any direct damage to your
bones or teeth. The stories you may have heard that
methadone ‘gets into the bones’ are not true.
Will I have to take my dose in front of
the pharmacist?
Taking medication at the chemist in front of a pharmacist
is called ‘supervised consumption.’ Most people will have
to take it under supervised consumption to start with as
it is the best way of ensuring you are taking your
methadone safely and correctly. If you can show your
doctor that you are stabilised on methadone (i.e. you are
not using heroin or other drugs bought illicitly) there is
no reason why you should not ask to have take-home
doses of methadone. This should be possible after a
period of months, unless there are good reasons such
as working or child care for it to be less. Ultimately
however, this is a decision that only your GP or prescriber
can make.
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Usual problems and solutions
A computer generated date is not acceptable, even
where a prescriber has an own handwriting exemption,
however a prescriber may use a date stamp or write the
date in ink on the form.
Home Office ruling on missed collections
of instalments:
 If a patient fails to collect an instalment on the due
date then that dose is forfeited. The pharmacist cannot
dispense or supply the dose on the following day.
However, the Home Office has provided the following,
helpful advice in the case of missed days where the
instalment is for more than one day.
 ‘Instalment prescriptions covering more than one day
should be collected on the specified day; if this
collection is missed the remainder of the
instalment (i.e. the instalment less the amount
prescribed for the day(s) missed) may be
supplied.’
The advice from the Home Office goes on to state that
their legal advice is that regulation 15(1)(g) does not
necessarily require a regular interval to be specified in
the direction (from the prescriber). For this reason, a
direction that enables the remainder of the prescription
to be collected the following day conforms with that
regulation and that the statement above is clear and
unambiguous.
Prescribers are thus advised to use the above direction
on prescriptions that are for intervals greater than one
day. Without the direction the patient will forfeit the whole
of the instalment.
Another useful tip is to write ‘and in advance for days
of closure’ after the dispensing instructions on the
prescription means the pharmacist can adjust for
weekends and other times when the pharmacy is shut,
without more specific instructions.
For the future
One recommendation of the Fourth Report of the
Shipman Inquiry is that pharmacists should be allowed
to endorse ‘technical errors/omissions’ on prescriptions
for Schedule 2 and 3 CDs after confirming the intention
of the prescriber with him/her.
It is anticipated that machine/computer generated
prescriptions and controlled drugs records will
become legal in the near future.
Appendix 3
Travel abroad
Home Office Export Licence is required for those
wishing to travel abroad with amounts in excess
of 500 mg of methadone.
Once proof of travel has been established a letter,
giving 14 days notice, needs to be faxed or posted to:
Home Office, Drugs Branch,
2 Marsham Street, London SW1P 4DF
Tel: 020 7035 0472
Fax: 020 7035 6161
 The letter needs to clearly state the name and address
of the person travelling, date of birth, the quantity of
drugs to be carried, the strength and form in which
the drugs will be dispensed and the dates of travel to
and from the UK.
 The Licence only permits export. It does not guarantee
that the country being travelled to will allow the person
and their drugs into the country. This should be clearly
explained to the patient and they should check with
the relevant embassy whether they could import
the drugs.
 Some countries will not allow the import of all
controlled drugs and others only certain drugs.
 It is good practice to provide a ‘to whom it may
concern’ letter that the patient can carry with them
stating that they are engaged in treatment, this being
the reason they are carrying the drugs.
 Specific requirements for different countries can
change and it is always best to check with the
individual embassies.
For more information visit the Home Office website on
www.homeoffice.gov.uk
A very useful website to visit for more information about
travel abroad is: http://www.indro-online.de/travel.htm
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How to write a prescription
Prescriptions for methadone must be signed and dated
by the prescriber, with the date of signing, and specify
the prescriber’s address. At present a CD prescription
is valid for 13 weeks from the date stated. This means
that the prescription can be dispensed within 13 weeks
after the date on which it was issued. In addition, it is
good practice to write the starting date on the prescription.
This will ensure that if the patient is already in receipt of
a prescription there is no chance of an inadvertent ‘overlap’
of dates that could result in a double supply of methadone.
The prescription must specify:
 The name and address of the patient.
 The form of the preparation e.g. mixture; ‘sugar free.’
 The strength of the methadone preparation e.g.; 1 mg/ml.
 The daily dose to be taken e.g. 80 ml daily.
 The total quantity of the preparation OR the number
of dosage units in both words and figures e.g. 500 ml
(Five hundred ml); 500 mg (five hundred milligrams).
 Be signed and dated by the prescriber.
 Instructions to cover when the pharmacy is closed
e.g. Sundays and Bank Holidays.
 The provision for patients to receive daily supplies of
methadone on form FP10 (MDA) or GP10 (3) in 
Scotland is an administrative arrangement made
under the National Health Service and does not form
part of the Misuse of Drugs Regulations.
 In the case of a prescription for a total quantity to be
dispensed in instalments, the prescription must contain
a clear and unambiguous direction specifying the
amount that must be supplied on each occasion and
the intervals to be observed when supplies are to be
made. e.g. 80 ml to be supplied daily in instalments;
80ml daily, 160 ml to be supplied on Monday and
Wednesday and 240 ml to be supplied in Fridays;
80 ml to be supplied daily in instalments Monday
to Friday and 160 ml on Saturdays.
Handwriting exemptions
Practitioners treating more than ten patients or more
per week for dependence may apply to the Home
Office for an ‘own handwriting exemption certificate.’
Application form (MD 40A) and guidance notes can
be obtained via the Home Office Website
http://www.homeoffice.gov.uk/drugs/licensing/index.html.
Please note that ‘own handwriting’ exemptions apply to
the specified prescriber at a specified address. If you
practise at more than one site you will need an exemption
for each site. It is expected that the own handwriting
requirement will be repealed in the near future.
Appendix 2
Writing prescriptions
All prescriptions for the use of methadone in the treatment of opiate dependence should be written on the form FP10
(MDA), in England and Wales or GP10 (3) in Scotland. This form allows the prescribing of 14 days supply of methadone
to be dispensed in instalments.
Incomplete or inaccurately written prescriptions for CDs such as methadone can cause real problems for patients,
prescribers and pharmacists. It is an offence for a prescriber to issue an incomplete prescription and a pharmacist is
not allowed to dispense a CD unless all the information required by law is present on the prescription. Therefore, it is
in the best interest of all concerned to ensure that the strict requirements of the law are complied with before the
prescription leaves the practice.
Full details on how to write a prescription for preparations covered by Schedules 2 and 3 of the Misuse of Drugs
Regulations 2001 (SI 3998) can be found on page 7 of the British National Formulary (see Controlled Drugs
and Dependence).
Prescriptions for methadone must comply with the requirements of Schedules 15 and 16 of the Regulations.
These cover the form and the provisions as to supply on a prescription of Schedules 2 and 3 CDs.
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of dates that could result in a double supply of methadone.
The prescription must specify:
 The name and address of the patient.
 The form of the preparation e.g. mixture; ‘sugar free.’
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of dosage units in both words and figures e.g. 500 ml
(Five hundred ml); 500 mg (five hundred milligrams).
 Be signed and dated by the prescriber.
 Instructions to cover when the pharmacy is closed
e.g. Sundays and Bank Holidays.
 The provision for patients to receive daily supplies of
methadone on form FP10 (MDA) or GP10 (3) in 
Scotland is an administrative arrangement made
under the National Health Service and does not form
part of the Misuse of Drugs Regulations.
 In the case of a prescription for a total quantity to be
dispensed in instalments, the prescription must contain
a clear and unambiguous direction specifying the
amount that must be supplied on each occasion and
the intervals to be observed when supplies are to be
made. e.g. 80 ml to be supplied daily in instalments;
80ml daily, 160 ml to be supplied on Monday and
Wednesday and 240 ml to be supplied in Fridays;
80 ml to be supplied daily in instalments Monday
to Friday and 160 ml on Saturdays.
Handwriting exemptions
Practitioners treating more than ten patients or more
per week for dependence may apply to the Home
Office for an ‘own handwriting exemption certificate.’
Application form (MD 40A) and guidance notes can
be obtained via the Home Office Website
http://www.homeoffice.gov.uk/drugs/licensing/index.html.
Please note that ‘own handwriting’ exemptions apply to
the specified prescriber at a specified address. If you
practise at more than one site you will need an exemption
for each site. It is expected that the own handwriting
requirement will be repealed in the near future.
Appendix 2
Writing prescriptions
All prescriptions for the use of methadone in the treatment of opiate dependence should be written on the form FP10
(MDA), in England and Wales or GP10 (3) in Scotland. This form allows the prescribing of 14 days supply of methadone
to be dispensed in instalments.
Incomplete or inaccurately written prescriptions for CDs such as methadone can cause real problems for patients,
prescribers and pharmacists. It is an offence for a prescriber to issue an incomplete prescription and a pharmacist is
not allowed to dispense a CD unless all the information required by law is present on the prescription. Therefore, it is
in the best interest of all concerned to ensure that the strict requirements of the law are complied with before the
prescription leaves the practice.
Full details on how to write a prescription for preparations covered by Schedules 2 and 3 of the Misuse of Drugs
Regulations 2001 (SI 3998) can be found on page 7 of the British National Formulary (see Controlled Drugs
and Dependence).
Prescriptions for methadone must comply with the requirements of Schedules 15 and 16 of the Regulations.
These cover the form and the provisions as to supply on a prescription of Schedules 2 and 3 CDs.
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For additional copies, and for further information about training on cocaine, crack
and other issues relevant to primary care based drug and alcohol treatment,
please contact
Jo Betterton
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This guidance, and other resources including an interactive discussion forum,
are available on the SMMGP website at www.smmgp.org.uk
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